2026-10-02 · data · ●●● · published 2026-10-02corrected
WHO's Global Health Estimates 2000–2023, released 2 October 2026, put global healthy life expectancy (HALE) at birth (WHO global aggregate) at 62.8 years in 2023, still 0.4 years below its 2019 level, while the unweighted median HALE at birth across 185 countries (GHO WHOSIS_000002, both sexes) reached 63.8 years in 2023, above its 2019 value of 63.6 years.
2026-09-29 · analysis · ●○○ · published 2026-09-29verified
PAHO's Health in the Americas 2026 reported that life expectancy in the Region of the Americas reached 77.1 years in 2023, exceeding pre-pandemic levels, but that between 2000 and 2023 healthy life expectancy rose only about 1.5 years versus nearly 4 years for life expectancy.
2026-07-24 · data · ●○○ · published 2026-07-24verified
Japan's Ministry of Health, Labour and Welfare 2025 abridged life table put life expectancy at birth at 81.35 years for men and 87.33 years for women in 2025, up 0.25 and 0.20 years from 2024.
2026-07-21 · analysis · ●●○ · published 2026-07-21verified
A GBD 2023 study published in The Lancet Public Health (IHME release, 21 July 2026) found that global healthy life expectancy at birth rose from 55.9 to 63.1 years between 1990 and 2023 while life expectancy rose from 64.6 to 73.8 years, widening the global morbidity gap (years lived in poor health) from 8.8 to 10.7 years.
2026-07-13 · policy · ●○○ · published 2026-07-13corrected
China's State Council issued its national health plan for the 15th Five-Year Plan period (2026–2030), targeting an average life expectancy of 80 years by 2030, up from 79.25 years in 2025.
2026-05-13 · data · ●●○ · published 2026-05-13verified
WHO's World Health Statistics 2026 reported that global healthy life expectancy (HALE) at birth, after rising from 58 years in 2000 to 63 years in 2019, fell to 61 years in 2021 and recovered to 62 years in 2022 and 63 years in 2023, with female (64 years) and male (62 years) HALE in 2023 still slightly below their 2019 levels.
2026-03-26 · setback · ●○○ · published 2026-03-26corrected
The UN Population Division's programme plan note to the Commission on Population and Development (E/CN.9/2026/CRP.1, 26 March 2026) states that the release of the World Population Prospects has been postponed from 2026 to 2027, amid liquidity constraints that also prevented the subprogramme from recruiting staff.
2026-03-07 · data · ●●○ · published 2026-03-07corrected
China's National Health Commission head Lei Haichao said on 7 March 2026 that the average life expectancy of Chinese people reached 79.25 years in 2025, an increase of 1.32 years from 2020.
2026-02-19 · data · ●●○ · published 2026-02-19verified
The UK Office for National Statistics reported that healthy life expectancy at birth (expected years in 'good' self-rated general health) in the UK for 2022–2024 was 60.7 years for males and 60.9 years for females, down 1.8 and 2.5 years from 2019–2021 and the lowest since the series began in 2011–2013.
2025 · data · ●●● · published 2025-12-31legacy
WHO World Health Statistics 2025 reported that global healthy life expectancy (HALE) at birth fell by 1.6 years between 2019 and 2021 during the COVID-19 pandemic, rolling it back to 2012 levels.
2025-12 · data · ●●○ · published 2025-12-10verified
The UK Office for National Statistics (Dec 2025) reported life expectancy at birth for 2022–2024 of 83.0 years for females (recovered to pre-COVID 2019 levels) and 79.1 years for males (still about 10 weeks below pre-COVID levels).
↳ corrects (or adds sources to) an earlier record: 2025-12: The UK Office for National Statistics (Dec 2025) reported life expectancy at birth for…
2025-07-09 · data · ●○○ · published 2025-11-30corrected
A JAMA study found California life expectancy in 2024 remained 0.86 years below its 2019 level, while the Black-White life expectancy gap was 6.52 years versus 5.67 years in 2019.
↳ corrects (or adds sources to) an earlier record: 2025-11: A JAMA study (Nov 2025) found California life expectancy still 0.86 years below its…
2024 · data · ●○○ · published 2026-01-29verified
NCHS final 2024 mortality data put US life expectancy at birth at 79.0 years in 2024 (81.4 for females, 76.5 for males), up 0.6 years from 78.4 years in 2023.
↳ corrects (or adds sources to) an earlier record: 2024: US life expectancy at birth was 79.25 years in 2024.
2021 · data · ●●● · published 2026-01-04verified
WHO Global Health Estimates put population-weighted global healthy life expectancy (HALE) at birth at 61.9 years in 2021, the latest year with official data.
↳ corrects (or adds sources to) an earlier record: 2021: WHO Global Health Estimates put population-weighted global healthy life expectancy…
2020 · data · ●○○ · published 2026-01-04verified
WHO Global Health Observatory data put global healthy life expectancy (HALE) at birth at 62.8 years in 2020, down from 63.5 years in 2019.
↳ corrects (or adds sources to) an earlier record: 2020: WHO Global Health Observatory data put global healthy life expectancy (HALE) at birth…
2019 · data · ●●○ · published 2026-01-04corrected
WHO reports global healthy life expectancy (HALE) at birth increased 9%, from 58.1 years in 2000 to 63.5 years in 2019, a 5.3-year increase.
↳ corrects (or adds sources to) an earlier record: 2019: According to WHO, global healthy life expectancy (HALE) at birth rose by 5.4 years…
2019 · data · ●●○ · published 2026-01-04verified
WHO Global Health Estimates put population-weighted global healthy life expectancy (HALE) at birth at 63.5 years in 2019, the pre-pandemic peak.
↳ corrects (or adds sources to) an earlier record: 2019: WHO Global Health Estimates put population-weighted global healthy life expectancy…
2026-10-13 · setback · ●○○ · published 2026-10-13verified
BioNTech announced on 13 October 2026 that the phase 2/3 AHEAD-MERIT trial of its mRNA cancer immunotherapy BNT113 plus pembrolizumab in HPV16-positive metastatic head and neck cancer missed its first dual primary endpoint of progression-free survival versus pembrolizumab alone, with the trial continuing to its overall-survival endpoint.
2026-10-08 · achievement · ●●○ · published 2026-10-08corrected
On 8 October 2026 the FDA approved atezolizumab with fluoropyrimidine and oxaliplatin chemotherapy as adjuvant treatment of stage III mismatch repair-deficient colon cancer, based on ATOMIC, where adding atezolizumab to mFOLFOX6 improved disease-free survival versus mFOLFOX6 alone with a hazard ratio of 0.50 (3-year DFS 86.3% vs 76.2% in NEJM).
2026-09-24 · analysis · ●●○ · published 2026-09-24verified
IARC Handbooks of Cancer Prevention Volume 21 (special report in NEJM, 24 September 2026) concluded that low-dose CT screening of high-risk individuals reduces lung cancer mortality and the incidence of late-stage lung cancer.
2026-09-13 · achievement · ●●○ · published 2026-09-13verified
At the IASLC World Conference on Lung Cancer on 13 September 2026, the China-only phase 3 HARMONi-2 trial in 398 patients with treatment-naive PD-L1-positive advanced NSCLC reported that ivonescimab monotherapy improved median overall survival to 30.8 versus 22.6 months with pembrolizumab (HR 0.73).
2026-09-04 · achievement · ●●○ · published 2026-09-04verified
On 4 September 2026 the FDA granted accelerated approval to camizestrant (Etcamah) with a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer upon detection of an ESR1 mutation in blood ctDNA during aromatase inhibitor plus CDK4/6 inhibitor therapy, based on SERENA-6, where switching gave median progression-free survival of 16 versus 9.2 months (HR 0.44).
2026-08-28 · setback · ●●○ · published 2026-08-28verified
BioNTech announced on 28 August 2026 that its phase 2 trial of the individualized mRNA cancer vaccine autogene cevumeran in resected ctDNA-positive colorectal cancer was terminated on the data monitoring committee's recommendation after it found a numerical imbalance in overall survival between arms and judged further continuation unlikely to change the efficacy outcome.
2026-08-26 · achievement · ●●● · published 2026-08-26verified
On 26 August 2026 the FDA approved daraxonrasib (Rasonque), an inhibitor of the RAS GTPase family, for previously treated metastatic pancreatic adenocarcinoma, based on RASolute 302, where median overall survival was 13.2 versus 6.7 months with standard chemotherapy (HR 0.40).
2026-08-25 · achievement · ●●○ · published 2026-08-25verified
On 25 August 2026 the FDA approved first-line zanidatamab plus tislelizumab and chemotherapy for HER2-positive advanced gastric, gastroesophageal junction or esophageal adenocarcinoma, based on HERIZON-GEA-01, where median overall survival was 26.4 versus 19.2 months with trastuzumab plus chemotherapy (HR 0.72).
2026-08-19 · achievement · ●●● · published 2026-08-19verified
Merck and Moderna announced on 19 August 2026 that the phase 3 INTerpath-001 trial in 1,137 patients with resected stage IIB–IV melanoma met its primary endpoint of recurrence-free survival and key secondary endpoint of distant metastasis-free survival for the individualized mRNA neoantigen therapy intismeran autogene plus pembrolizumab versus pembrolizumab alone, the first positive phase 3 for an mRNA-based cancer therapy (effect sizes not yet disclosed; overall survival still being evaluated).
2026-08-06 · achievement · ●●○ · published 2026-08-06verified
A Nature Medicine phase 1 trial published 6 August 2026 of intracranially infused autologous B7-H3-targeting CAR-T cells (TX103) in 15 patients with recurrent glioblastoma found no dose-limiting toxicities, a 12-month overall survival rate of 66.7% and median overall survival of 19.1 months from first infusion (uncontrolled).
2026-07-31 · achievement · ●○○ · published 2026-07-31verified
Johns Hopkins researchers reported in Cell Press Blue on 31 July 2026 that the DELFI cell-free-DNA fragmentome liver-cancer classifier, validated in blood from 377 people in Guatemala and Romania with differing liver-cancer causes, consistently detected hepatocellular carcinoma and, combined with AFP and age and sex, detected early- and late-stage cancers with greater sensitivity than existing blood testing alone; prospective validation is still to come.
2026-07-14 · achievement · ●●○ · published 2026-07-14verified
On 14 July 2026 the FDA approved gedatolisib (Revtorpyk) with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative advanced breast cancer without a PIK3CA mutation after endocrine therapy, based on VIKTORIA-1, where median progression-free survival with the triplet was 9.3 versus 2.0 months with fulvestrant (HR 0.24).
2026-07-10 · achievement · ●●○ · published 2026-07-10verified
On 10 July 2026 the FDA extended perioperative pembrolizumab plus enfortumab vedotin for muscle-invasive bladder cancer to cisplatin-eligible patients, based on KEYNOTE-B15/EV-304, where the regimen improved event-free survival (HR 0.53) and overall survival (HR 0.65) versus neoadjuvant gemcitabine and cisplatin.
2026-07-08 · analysis · ●○○ · published 2026-07-08verified
WHO's Global Status Report on Cancer 2026 (8 July 2026, with IARC) reported that 5-year breast cancer survival is 87% in high-income countries but only about 42% in low-income countries, and that fewer than one in three countries include cancer care in their universal health coverage packages.
2026-07-08 · data · ●●○ · published 2026-07-08verified
IARC and the American Cancer Society's GLOBOCAN 2024 estimates (published 8 July 2026) put the global cancer burden at 20.6 million new cases and 9.8 million deaths in 2024 across 34 cancer types in 186 countries, with incidence projected to rise 67% to 34.4 million cases by 2050.
2026-06-30 · achievement · ●●● · published 2026-06-30corrected
On 30 June 2026 the FDA approved Orca Biosystems' Tregzi, the first regulatory T (Treg) cell-based immunotherapy, for adults with blood cancers undergoing allogeneic stem cell transplantation, based on the 187-patient randomized PRECISION-T trial in which 1-year chronic-GVHD-free survival was 78% versus 38.4% with a standard transplant and serious chronic GVHD within one year occurred in 12.6% versus 44%.
2026-06-25 · data · ●●○ · published 2026-06-25verified
A NEJM report dated 25 June 2026 on 38 patients with relapsed/refractory B-cell lymphoma treated with a single CD19 CAR-T infusion (tisagenlecleucel) found no relapses beyond 5.4 years over a median 10.1-year follow-up, with 10-year lymphoma-free survival of 32% in large B-cell lymphoma and 47% in follicular lymphoma, alongside 21% 10-year cumulative incidence of second cancers.
2026-06-22 · achievement · ●●● · published 2026-06-22verified
On 22 June 2026 China's NMPA approved CARsgen's satricabtagene autoleucel (satri-cel), an autologous Claudin18.2-targeted CAR T-cell therapy, for Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma after at least two prior lines of therapy, the world's first approved CAR-T therapy for a solid tumor.
2026-06-04 · achievement · ●●○ · published 2026-06-04corrected
A Francis Crick Institute/UCL study published in Cell on 4 June 2026 used plasma data from over 48,000 people to identify a 14-protein inflammatory signature that predicts lung cancer more than 5 years before diagnosis, validated across eight cohorts; in a re-analysis of 4,651 CANTOS participants, those with a high signature had their lung cancer risk almost halved by the IL-1β blocker canakinumab (number needed to treat 55), though critics note several of the proteins are non-specific tumour markers.
2026-06-01 · achievement · ●●○ · published 2026-06-01verified
Kelonia reported at ASCO on 1 June 2026 that in the phase 1 inMMyCAR study of KLN-1010, a single infusion generating BCMA CAR-T cells in vivo without preparative chemotherapy, 18 relapsed/refractory myeloma patients had been dosed with a 100% overall response rate and MRD-negative marrow in all evaluable patients, the first patient remaining in MRD-negative response beyond 10 months, and all cytokine release syndrome grade 1–2 (16 of 18).
2026-05-31 · achievement · ●●○ · published 2026-05-31corrected
Johnson & Johnson reported on 31 May 2026 (ASCO plenary, NEJM) that in the phase 3 PROTEUS trial in 2,109 men with high-risk localized or locally advanced prostate cancer, perioperative apalutamide plus androgen deprivation therapy reduced the risk of metastasis or death by 20% (HR 0.80; 5-year metastasis-free survival 78.2% vs 73.5%).
2026-05-31 · achievement · ●●○ · published 2026-05-31verified
Akeso reported on 31 May 2026 (ASCO plenary, The Lancet) that in the China-only phase 3 HARMONi-6 trial in 532 patients with first-line advanced squamous non-small cell lung cancer, the PD-1/VEGF bispecific ivonescimab plus chemotherapy reduced the risk of death by 34% versus tislelizumab plus chemotherapy (HR 0.66; median overall survival 27.9 vs 23.7 months).
2026-05-28 · policy · ●●○ · published 2026-05-28verified
The UK National Screening Committee, in minutes of its March 2026 meeting published 28 May 2026, confirmed a recommendation for the UK's first prostate cancer screening programme, targeted at men aged 45–61 with a pathogenic BRCA2 variant and relevant family history (PSA every 2 years), and against population prostate screening.
2026-05-22 · achievement · ●●○ · published 2026-05-22verified
On 22 May 2026 the FDA approved datopotamab deruxtecan (Datroway) for unresectable or metastatic triple-negative breast cancer in patients who are not candidates for PD-1/PD-L1 inhibitors, based on TROPION-Breast02, where median overall survival was 23.7 versus 18.7 months with chemotherapy (HR 0.79).
2026-05-15 · achievement · ●●○ · published 2026-05-16corrected
On 15 May 2026 the FDA approved trastuzumab deruxtecan for two HER2-positive early-stage breast cancer indications: neoadjuvant use before THP (DESTINY-Breast11 pathological complete response 67.3% vs 56.3% with dose-dense doxorubicin-cyclophosphamide followed by THP) and post-neoadjuvant residual invasive disease (DESTINY-Breast05 3-year invasive disease-free survival 92.4% vs 83.7% with T-DM1, HR 0.47).
2026-05-15 · achievement · ●●○ · published 2026-05-15verified
On 15 May 2026 the FDA approved adjuvant atezolizumab after cystectomy for muscle-invasive bladder cancer with ctDNA-detected molecular residual disease, based on IMvigor011, where median overall survival was 32.8 versus 21.1 months with placebo (HR 0.59).
2026-05-01 · achievement · ●●○ · published 2026-05-01verified
On 1 May 2026 the FDA approved vepdegestrant (Veppanu), a heterobifunctional protein degrader, for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after endocrine therapy, based on VERITAC-2, where median progression-free survival in the ESR1-mutated population was 5 versus 2.1 months with fulvestrant (HR 0.57).
2026-04 · data · ●●○ · published 2026-04-19verified
Follow-up of the 16-patient phase 1 trial of the individualized mRNA vaccine autogene cevumeran after pancreatic cancer surgery, presented at AACR 2026, found that 7 of the 8 vaccine immune responders (87.5%) were alive 4 to 6 years after surgery, versus 2 of the 8 non-responders (median survival 3.4 years).
2026-04-23 · data · ●●○ · published 2026-04-23verified
Cancer Research UK's Cancer in the UK 2026 report (23 April 2026) stated that roughly 6% to 7% of UK cancer patients are diagnosed through screening, and estimated England could raise this to around 9% (about 11,000 extra screen-detected cancers) by expanding and optimising its breast, bowel, cervical and lung screening programmes.
2026-04-22 · data · ●●○ · published 2026-04-22verified
With its 22 April 2026 data release (incidence through 2023, US mortality through 2024), NCI's SEER Cancer Stat Facts put US 5-year relative survival for cancer of any site at 70.5% for patients diagnosed in 2016–2022.
2026-04-20 · announcement · ●●○ · published 2026-04-20verified
On 20 April 2026 Eli Lilly agreed to acquire in vivo CAR-T developer Kelonia Therapeutics for up to $7.0 billion in cash, including $3.25 billion upfront, for its lentiviral in vivo gene-delivery platform and lead program KLN-1010, a one-time infusion that generates BCMA CAR-T cells inside myeloma patients.
2026-04-13 · achievement · ●●● · published 2026-04-13verified
Revolution Medicines announced on 13 April 2026 that in the phase 3 RASolute 302 trial in previously treated metastatic pancreatic ductal adenocarcinoma, the oral RAS(ON) inhibitor daraxonrasib achieved a median overall survival of 13.2 months versus 6.7 months with chemotherapy (HR 0.40) in the intent-to-treat population.
2026-04-13 · achievement · ●●○ · published 2026-04-13corrected
Allogene reported on 13 April 2026 that at the interim futility analysis of the pivotal randomized phase 2 ALPHA3 trial of its off-the-shelf allogeneic CAR-T cema-cel as first-line consolidation in large B-cell lymphoma, 58.3% (7/12) of cema-cel patients achieved MRD negativity versus 16.7% (2/12) under observation at the data cutoff triggered when the 24th patient completed the day-45 MRD assessment (EFS, PFS and OS endpoints remain blinded).
2026-04-01 · policy · ●●○ · published 2026-04-01corrected
On 1 April 2026 Germany launched a national statutory-insurance-funded low-dose CT lung cancer screening programme for people aged 50–75 with a heavy smoking history (at least 25 years and 15 pack-years), following a June 2025 G-BA decision.
2026-03-26 · data · ●●○ · published 2026-03-26verified
CONCORD-4 childhood-cancer results (The Lancet, online 26 March 2026), the first CONCORD cycle to include all childhood cancers, covering 613,021 children diagnosed 1990–2019 in 307 registries in 68 countries, found a 5-year Cancer Survival Index (net survival) for all childhood cancers combined above 80% in most high-income countries for children diagnosed in 2015–2019, 60–80% in most upper-middle-income countries and 50–60% in five lower-middle-income countries.
2026-03-25 · achievement · ●●○ · published 2026-03-25verified
On 25 March 2026 the FDA approved relacorilant (Lifyorli), a glucocorticoid receptor antagonist, with nab-paclitaxel for platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, based on ROSELLA, where median overall survival was 16 versus 11.9 months (HR 0.65).
2026-03-25 · achievement · ●●○ · published 2026-03-25corrected
A Nature Medicine phase 1 report published 25 March 2026 of ESO-T01, an immune-shielded lentiviral vector generating BCMA CAR-T cells in vivo without leukapheresis or lymphodepletion, in 5 patients with relapsed/refractory myeloma found 4 objective responses including 3 stringent complete remissions (MRD-negative in all 4 evaluable responders by day 60), but all patients had grade ≥3 adverse events, one died, and the trial was stopped early in 2025.
2026-03-05 · achievement · ●●○ · published 2026-03-05corrected
On 5 March 2026 the FDA approved teclistamab (Tecvayli) with daratumumab hyaluronidase for adults with relapsed or refractory multiple myeloma after at least one prior line including a proteasome inhibitor and an immunomodulatory agent, and converted its late-line (≥4 prior lines) monotherapy accelerated approval to traditional, based on MajesTEC-3 (587 patients), where progression-free survival improved with a hazard ratio of 0.17 (median not reached vs 18.1 months) and overall survival with a hazard ratio of 0.46.
2026-02-27 · achievement · ●●○ · published 2026-02-27verified
The EORTC reported on 27 February 2026 final results of the phase 3 PEACE-3 trial: first-line enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer with bone metastases improved median overall survival to 38.2 versus 32.6 months with enzalutamide alone (HR 0.76).
2026-02-24 · achievement · ●●○ · published 2026-02-24corrected
On 24 February 2026 the FDA granted traditional approval to encorafenib plus cetuximab and fluorouracil-based chemotherapy for BRAF V600E-mutated metastatic colorectal cancer (after a 2024 accelerated approval with cetuximab and mFOLFOX6), based on BREAKWATER, where median overall survival with encorafenib, cetuximab and mFOLFOX6 was 30.3 versus 15.1 months with control chemotherapy (HR 0.49).
2026-02-18 · achievement · ●●○ · published 2026-02-18corrected
A Nature study published 18 February 2026 of BioNTech's individualized neoantigen mRNA vaccine given to 14 patients with triple-negative breast cancer after surgery and neoadjuvant or adjuvant therapy reported high-magnitude, mostly de novo vaccine-induced T-cell responses in nearly all patients that stayed functional for several years, with 11 patients relapse-free for up to six years post-vaccination (open-label first-in-human phase 1 study arm).
2026-02-10 · achievement · ●●○ · published 2026-02-10verified
On 10 February 2026 the FDA approved pembrolizumab plus paclitaxel (with or without bevacizumab) for PD-L1-positive (CPS≥1) platinum-resistant ovarian, fallopian tube or primary peritoneal carcinoma, based on KEYNOTE-B96, where median overall survival was 18.2 versus 14.0 months (HR 0.76).
2026-02-04 · policy · ●●○ · published 2026-02-04verified
England's National Cancer Plan (4 February 2026) premised its survival ambition on raising the share of cancers diagnosed at stage 1–2 by at least 20 percentage points above the 2019 level by 2035, committed to completing national lung cancer screening rollout by 2030 and increasing bowel screening sensitivity, and pledged an implementation plan to offer multi-cancer early detection tests at scale if the UK NSC judges them effective.
2026-02-04 · policy · ●●○ · published 2026-02-04verified
England's National Cancer Plan (DHSC and NHS England, 4 February 2026) set the goal that three-quarters of people diagnosed with cancer in 2035 are cancer-free or living well with cancer after 5 years, up from a projected 60% in 2022, and aims to save 320,000 more lives by 2035.
2026-02-03 · policy · ●●○ · published 2026-02-03corrected
The US Consolidated Appropriations Act, 2026, signed on 3 February 2026, gave the National Cancer Institute $7.35 billion for FY2026, $128 million more than its FY2025 enacted level, instead of the 37.3% cut the administration had requested.
2026-01-29 · achievement · ●●○ · published 2026-01-29verified
An NIH-funded retrospective study published in Clinical Cancer Research on 29 January 2026 found that adding the proteins ANPEP and PIGR to CA19-9 and THBS2 gave a four-marker blood panel that distinguished pancreatic ductal adenocarcinoma from non-cases 91.9% of the time across all stages at a 5% false-positive rate and identified 87.5% of stage I/II cases, with prediagnostic studies in asymptomatic people still needed before screening use.
2026-01-29 · achievement · ●●○ · published 2026-01-29verified
Final results of the Swedish MASAI randomised trial (over 100,000 women), published in The Lancet on 29 January 2026, found AI-supported mammography screening gave a non-inferior and 12% lower interval breast cancer rate than standard double reading (1.55 vs 1.76 per 1,000 participants) with fewer aggressive or advanced interval cancers, after earlier analyses showed 29% more screen-detected cancers without more false positives.
2026-01-20 · data · ●●○ · published 2026-01-20corrected
Korea's Ministry of Health and Welfare and Central Cancer Registry reported (January 2026) a nationwide 5-year relative survival rate of 73.7% for all cancers combined among patients diagnosed in 2019–2023 (69.6% excluding thyroid cancer, per the accompanying registry paper), up from 54.2% for 2001–2005, with 92.7% for localized-stage and 27.8% for distant-stage cancers.
2026-01-16 · achievement · ●●○ · published 2026-01-16corrected
A Nature Medicine phase 1b/2 trial published 16 January 2026 of Nous-209, an off-the-shelf viral-vectored vaccine encoding 209 shared frameshift neoantigens, in 45 healthy Lynch syndrome carriers found it safe with no intervention-related serious adverse events and induced neoantigen-specific T-cell responses in 100% of 37 evaluable participants, still detectable at 1 year in 85%, supporting its development for cancer interception (single-arm; a larger randomized study is needed to evaluate any reduction in cancer incidence).
2026-01-13 · data · ●●○ · published 2026-01-13corrected
The American Cancer Society's Cancer Statistics, 2026 (13 January 2026) reported that US 5-year relative survival for all cancers combined reached 70% for people diagnosed during 2015–2021, that 5-year survival for distant-stage disease (all cancers combined) doubled from 17% in the mid-1990s to 35%, and that the cancer mortality rate fell 34% from its 1991 peak through 2023, averting 4.8 million deaths.
2025 · achievement · ●○○ · published 2026-01-04verified
Trinity College Dublin researchers identified in 2025 a genetic weak spot in DMG, a childhood brain cancer.
↳ corrects (or adds sources to) an earlier record: 2025: Trinity College Dublin researchers identified in 2025 a genetic weak spot in DMG, a…
2025 · data · ●●○ · published 2026-01-04legacy
SEER cancer statistics give 5-year survival for stage IV (metastatic) disease of 31% for breast cancer, 8.2% for lung cancer and 15.6% for colorectal cancer in the US.
2025 · data · ●●● · published 2026-01-04corrected
In a phase 2b trial, personalized mRNA-4157 (V940) plus pembrolizumab reduced post-resection melanoma recurrence by 44% and distant metastasis risk by 65% compared with anti-PD-1 alone.
↳ corrects (or adds sources to) an earlier record: 2025: The personalized mRNA cancer vaccine mRNA-4157/V940 plus pembrolizumab for melanoma,…
2025 · achievement · ●○○ · published 2026-01-04verified
Manchester researchers discovered in 2025 a melanoma immunotherapy resistance mechanism, with potential solutions.
↳ corrects (or adds sources to) an earlier record: 2025: Manchester researchers discovered in 2025 a melanoma immunotherapy resistance…
2025 · achievement · ●○○ · published 2026-01-04corrected
In 2025, researchers in Italy developed a new drug molecule for tumors sensitive to NEDD4 expression and activity.
↳ corrects (or adds sources to) an earlier record: 2025: Researchers in Italy repurposed an antidepressant mechanism in 2025 for cancer drug…
2025 · setback · ●●○ · published 2026-01-04corrected
More than 18% of FDA's CDER and CBER employees were fired or quit in the first 9 months of 2025.
↳ corrects (or adds sources to) an earlier record: 2025: FDA staff attrition of more than 18% in 2025 is creating drug-approval bottlenecks, per…
2025 · data · ●●○ · published 2026-01-04verified
The FDA approved 46 novel drugs in 2025, with antibody-drug conjugates and bispecific antibodies dominating the oncology pipeline.
↳ corrects (or adds sources to) an earlier record: 2025: The FDA approved 46 novel drugs in 2025, with antibody-drug conjugates and bispecific…
2025 · achievement · ●○○ · published 2026-01-04corrected
CNIO researchers reported in 2025 that a very high-fat diet could make cancer spread easier and blood-clotting molecules may play a role.
↳ corrects (or adds sources to) an earlier record: 2025: CNIO researchers in Spain found in 2025 that a high-fat diet influences cancer…
2025 · data · ●○○ · published 2026-01-04corrected
Black patients' 5-year overall survival was 1% to 2% lower than White patients' for localized-stage cancers after stratifying by urbanicity, and 7% lower for regional-stage cancers in large metropolitan areas.
↳ corrects (or adds sources to) an earlier record: 2025: Black cancer patients in the US have 5-year survival rates 4–7% lower than White…
2025 · data · ●●○ · published 2026-01-04legacy
The mRNA cancer vaccine autogene cevumeran for pancreatic cancer, moving from Phase 1 to Phase 2, has induced immune responses persisting about 4 years.
2025-12 · achievement · ●●○ · published 2025-12-31verified
In December 2025 the FDA approved Breyanzi as the first CAR-T cell therapy for marginal zone lymphoma, which achieved a 95.5% response rate.
↳ corrects (or adds sources to) an earlier record: 2025-12: In December 2025 the FDA approved Breyanzi as the first CAR-T cell therapy for marginal…
2025 · data · ●○○ · published 2025-12-31verified
ACS Cancer Facts & Figures 2025 reports an 86% 10-year survival rate for invasive breast cancer in the US.
↳ corrects (or adds sources to) an earlier record: 2025: ACS Cancer Facts & Figures 2025 reports an 86% 10-year survival rate for invasive…
2025 · data · ●○○ · published 2025-12-31corrected
ACS Cancer Facts & Figures 2025 reports a 5-year relative survival rate of 13% for all stages of pancreatic cancer.
↳ corrects (or adds sources to) an earlier record: 2025: ACS Cancer Facts & Figures 2025 reports a 5-year survival rate of 8% for pancreatic…
2025 · data · ●●○ · published 2025-12-31verified
ACS Cancer Facts & Figures 2025 reports a 69% 5-year relative survival rate for all cancers combined in the US.
↳ corrects (or adds sources to) an earlier record: 2025: ACS Cancer Facts & Figures 2025 reports a 69% 5-year relative survival rate for all…
2025 · policy · ●●○ · published 2025-10-31corrected
The US FY2026 budget request proposed a 37.3% decrease in the National Cancer Institute budget from FY2025.
↳ corrects (or adds sources to) an earlier record: 2025: The US FY2026 budget request for NIH cancer research funding is 37% below the FY2025…
2025-11-19 · achievement · ●●○ · published 2026-01-04verified
On 19 November 2025 the FDA granted full approval to tarlatamab for extensive-stage small cell lung cancer.
↳ corrects (or adds sources to) an earlier record: 2025-11-19: On 19 November 2025 the FDA granted full approval to tarlatamab for extensive-stage…
2025-10-01 · achievement · ●●○ · published 2025-10-03corrected
A Nature paper published on 1 October 2025 reported that Tex-PSR is a mechanistic driver of T-cell exhaustion and may be a target for cancer immunotherapy.
↳ corrects (or adds sources to) an earlier record: 2025-10-03: A Nature paper published on 3 October 2025 reported discovery of the TexPSR pathway,…
2025-09-25 · achievement · ●○○ · published 2025-09-25verified
On 25 September 2025 the FDA approved imlunestrant (Inluriyo), a SERD, for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
↳ corrects (or adds sources to) an earlier record: 2025-09-25: On 25 September 2025 the FDA approved imlunestrant (Inluriyo), a SERD, for ER-positive,…
2025-06-23 · achievement · ●○○ · published 2025-06-23verified
On 23 June 2025 the FDA granted accelerated approval to datopotamab deruxtecan (Datroway) for EGFR-mutated non-small cell lung cancer.
↳ corrects (or adds sources to) an earlier record: 2025-06-23: On 23 June 2025 the FDA granted accelerated approval to datopotamab deruxtecan…
2025-05-08 · achievement · ●●○ · published 2025-05-08verified
On 8 May 2025 the FDA granted accelerated approval to avutometinib plus defactinib, the first-ever treatment for KRAS-mutated recurrent low-grade serous ovarian cancer and a first novel/novel oral combination.
↳ corrects (or adds sources to) an earlier record: 2025-05-08: On 8 May 2025 the FDA granted accelerated approval to avutometinib plus defactinib, the…
2025-04-27 · achievement · ●●● · published 2025-04-27corrected
On 27 April 2025, a trial of neoadjuvant PD-1 blockade in early-stage mismatch repair-deficient solid tumors found that 84 of 103 patients who completed treatment had a clinical complete response and 82 did not undergo surgery.
↳ corrects (or adds sources to) an earlier record: 2025-04-27: On 27 April 2025 MSK researchers reported in NEJM that immunotherapy alone produced…
2025-03 · setback · ●●● · published 2026-01-04corrected
Federal funding for cancer research through March 2025 was 31% lower than in the same timeframe of the previous year.
↳ corrects (or adds sources to) an earlier record: 2025-03: US federal (NIH) cancer research funding decreased by 31% in January–March 2025.
2025-03-28 · achievement · ●●○ · published 2025-03-28verified
On 28 March 2025 the FDA expanded the indication of Pluvicto (lutetium-177 radioligand) to earlier-line treatment of metastatic castration-resistant prostate cancer.
↳ corrects (or adds sources to) an earlier record: 2025-03-28: On 28 March 2025 the FDA expanded the indication of Pluvicto (lutetium-177 radioligand)…
2025-02-14 · achievement · ●○○ · published 2025-02-14verified
On 14 February 2025 the FDA approved vimseltinib (Romvimza), a CSF1R kinase inhibitor, for symptomatic tenosynovial giant cell tumor.
↳ corrects (or adds sources to) an earlier record: 2025-02-14: On 14 February 2025 the FDA approved vimseltinib (Romvimza), a CSF1R kinase inhibitor,…
2025-01-17 · achievement · ●●○ · published 2025-01-17verified
On 17 January 2025 the FDA approved the antibody-drug conjugate datopotamab deruxtecan (Datroway) for unresectable or metastatic HR-positive/HER2-negative breast cancer.
↳ corrects (or adds sources to) an earlier record: 2025-01-17: On 17 January 2025 the FDA approved the antibody-drug conjugate datopotamab deruxtecan…
2025-01-16 · achievement · ●●○ · published 2026-01-04verified
On 16 January 2025 the FDA approved sotorasib plus panitumumab for KRAS G12C-mutated metastatic colorectal cancer.
↳ corrects (or adds sources to) an earlier record: 2025-01-16: On 16 January 2025 the FDA approved sotorasib plus panitumumab for KRAS G12C-mutated…
2026-10-09 · announcement · ●○○ · published 2026-10-09verified
On 9 October 2026 Natera announced that the FDA had granted Breakthrough Device designation to its cell-free-DNA multi-cancer early detection assay after assessing data from 12 cancer types; the test is not FDA approved.
- 2026-09-24 · IARC Handbooks of Cancer Prevention Volume 21 (special report in NEJM, 24 September 2026) concluded that low-dose CT screening of high-risk …
2026-09-23 · achievement · ●●● · published 2026-09-23verified
On 23 September 2026 the FDA's Molecular and Clinical Genetics advisory panel, reviewing the first PMA for a multi-cancer early detection test, voted 7–2 (one abstention) that the benefits of GRAIL's Galleri outweigh its risks for screening adults 50 and older, unanimously on safety and 6–4 on effectiveness; FDA's final decision was still pending.
2026-09-22 · achievement · ●●○ · published 2026-09-22corrected
The peer-reviewed PATHFINDER 2 results, published in Nature Medicine on 22 September 2026, reported that among 32,007 performance-analyzable adults aged 50+ without suspected cancer, GRAIL's Galleri test had a 0.54% cancer detection rate, 60.3% positive predictive value, 99.64% specificity, 91.3% cancer-signal-origin accuracy and episode sensitivity of 39.3% for all cancers and 69.8% for 12 prespecified deadly cancers, with 0.6% of 35,335 participants undergoing invasive procedures.
2026-09-22 · data · ●●○ · published 2026-09-22verified
The peer-reviewed NHS-Galleri primary results, published in NEJM on 22 September 2026 (142,250 randomised participants), confirmed no difference in stage III–IV incidence of 12 prespecified cancers after three screening rounds (incidence rate ratio 1.03, 95% CI 0.92–1.14) and a stage IV rate ratio of 0.86 (95% CI 0.74–1.00), with a companion Nature Medicine paper reporting per-round test specificity of about 99.5–99.6%.
2026-09-17 · policy · ●○○ · published 2026-09-17verified
On 17 September 2026 HHS appointed eight new members to the US Preventive Services Task Force, joining the eight remaining members of a panel that had not met since March 2025.
2026-09-16 · policy · ●○○ · published 2026-09-16verified
On 16 September 2026 the US House Ways and Means Committee unanimously advanced the bipartisan Alzheimer's Screening and Prevention (ASAP) Act, which would remove the legal barrier keeping Medicare from covering early Alzheimer's detection tests (committee passage, not enactment).
2026-09-10 · policy · ●●○ · published 2026-09-10corrected
An international consensus statement published in Diabetologia on 10 September 2026 and endorsed by multiple diabetes professional associations set out principles and minimum requirements for general-population screening for islet autoantibodies to diagnose early-stage (presymptomatic) type 1 diabetes, noting that 20–67% of children and adolescents currently present with diabetic ketoacidosis at clinical diagnosis.
2026-08-24 · achievement · ●●○ · published 2026-08-24verified
On 24 August 2026 the FDA cleared Roche's Elecsys pTau217 blood test, developed with Lilly, as the first single-biomarker blood test supporting both rule-in and rule-out of Alzheimer's amyloid pathology across primary and specialty care, for people 55 and older with signs, symptoms or complaints of cognitive decline (not asymptomatic screening).
2026-08-20 · achievement · ●●○ · published 2026-08-20verified
On 20 August 2026 the FDA cleared C2N Diagnostics' mass-spectrometry PrecivityAD2 blood test (Aβ42/40 plus %p-tau217) to aid identification of Alzheimer's amyloid pathology in adults aged 40 and older with cognitive symptoms; in a 1,142-person validation study its dual cutoffs gave a 97.6% positive and 93.1% negative predictive value, while the 17.3% of results in a third 'likely positive' category had a 77.3% positive predictive value.
2026-07-27 · achievement · ●●○ · published 2026-07-27corrected
On 27 July 2026 the FDA approved Freenome's SimpleScreen CRC blood test as a colorectal cancer screening option for average-risk adults 45 and older; in a Census-adjusted prespecified analysis of the more-than-48,000-participant PREEMPT CRC study it detected colorectal cancer with 81.1% sensitivity but advanced precancerous lesions with 13.7% sensitivity, with 90.4% specificity for advanced colorectal neoplasia.
2026-07-15 · data · ●●○ · published 2026-07-15corrected
A JAMA study presented at AAIC on 15 July 2026, pooling 2,684 cognitively unimpaired older adults (average age about 70) from six cohorts and trials, found that those with very high plasma p-tau217 had an estimated 38% absolute risk of progressing to cognitive impairment within 5 years and about 78% within 10 years (observational prognosis; the authors say further validation is needed before using it for individual prognosis).
2026-05-31 · data · ●●○ · published 2026-05-31verified
GRAIL's full 35,878-participant PATHFINDER 2 analysis presented at ASCO on 31 May 2026 showed adding Galleri to USPSTF A/B screenings increased screen-detected cancers 6.5-fold, with 53.0% of Galleri-detected new cancers at stage I–II, 60.3% PPV, 99.6% specificity and 69.8% episode sensitivity for the 12 deadliest cancers (39.3% for all cancers).
2026-05-30 · data · ●●○ · published 2026-05-30verified
Full NHS-Galleri results presented at ASCO on 30 May 2026 showed no reduction in combined stage III–IV cancers, but stage IV diagnoses of 12 prespecified cancers fell 9%, 22% and 26% in screening rounds one to three (14% overall), stage I–II diagnoses rose 16%, and the test had 52.0% PPV, 99.55% specificity and 54.7% episode sensitivity for the 12 cancers (30.7% for all cancers).
- 2026-05-28 · The UK National Screening Committee, in minutes of its March 2026 meeting published 28 May 2026, confirmed a recommendation for the UK's fir…
2026-05-27 · policy · ●●○ · published 2026-05-27corrected
The American Cancer Society's 2026 colorectal cancer screening guideline update (27 May 2026) reaffirmed screening of average-risk adults from age 45 through 75 and added blood-based tests (Shield) as an option only for people who decline or do not complete preferred screening tests, citing their lower sensitivity for advanced precancerous lesions and stage I cancers compared with established stool-based tests.
2026-05-11 · setback · ●●○ · published 2026-05-20verified
HHS Secretary Robert F. Kennedy Jr. dismissed US Preventive Services Task Force leaders John Wong and Esa Davis effective 11 May 2026, escalating disruption of the body whose A/B screening grades set no-cost-sharing coverage and which had not met since March 2025.
- 2026-04-23 · Cancer Research UK's Cancer in the UK 2026 report (23 April 2026) stated that roughly 6% to 7% of UK cancer patients are diagnosed through s…
2026-04-15 · policy · ●●○ · published 2026-04-15corrected
Bunkerhill Health announced on 15 April 2026 that CMS had established a new national billing code and payment under the Hospital Outpatient Prospective Payment System, effective 1 April 2026, for algorithmic analysis of coronary artery calcium and aortic valve calcium on chest CT scans, and that FDA had cleared its Contrast CAC and Contrast AVC algorithms, the first AI algorithms cleared to detect and quantify these on contrast-enhanced, routine non-gated chest CT.
- 2026-04-01 · On 1 April 2026 Germany launched a national statutory-insurance-funded low-dose CT lung cancer screening programme for people aged 50–75 wit…
2026-03-23 · announcement · ●●○ · published 2026-03-23corrected
On 23 March 2026 Abbott completed its acquisition of Exact Sciences, making Exact a wholly owned subsidiary and bringing the Cologuard noninvasive colorectal cancer screening test, the Cancerguard multi-cancer early detection blood test and the Oncodetect tumor-informed MRD test into Abbott.
2026-03-13 · policy · ●●○ · published 2026-03-13verified
The 2026 ACC/AHA multisociety dyslipidemia guideline (13 March 2026) recommends that every adult have lipoprotein(a) measured at least once, citing that Lp(a) of 125 nmol/L (50 mg/dL) or greater is associated with about a 1.4-fold and 250 nmol/L with at least a two-fold increased long-term risk of heart attack or stroke.
2026-03-13 · policy · ●●○ · published 2026-03-13verified
The 2026 ACC/AHA multisociety dyslipidemia guideline (13 March 2026) recommends selective coronary artery calcium scoring to detect subclinical atherosclerosis in borderline/intermediate-risk adults (initiating lipid-lowering therapy if CAC >0) and, as a class 1 recommendation, that incidental CAC found on noncardiac CT, including by validated AI algorithms, inform treatment decisions.
2026-03-11 · data · ●●○ · published 2026-03-11verified
CDC's National Diabetes Statistics Report (updated 11 March 2026) estimated that 27.6% of US adults with diabetes, about 11.0 million people, were undiagnosed (NHANES 2021–2023 data).
2026-02-19 · achievement · ●●○ · published 2026-02-19verified
A Nature Medicine study published 19 February 2026 (603 older adults in the Knight ADRC and ADNI cohorts) showed that the estimated age at plasma %p-tau217 positivity predicted the age of Alzheimer's symptom onset with a median absolute error of about 3–4 years, though NIH noted the models are not yet accurate enough for individual use.
2026-02-19 · setback · ●●● · published 2026-02-19verified
On 19 February 2026 GRAIL announced topline results of the 142,000-participant randomised NHS-Galleri trial: annual Galleri multi-cancer blood testing did not achieve the primary endpoint of a statistically significant reduction in stage III–IV diagnoses of 12 prespecified deadly cancers, although stage IV diagnoses fell by more than 20% in the second and third screening rounds and the overall cancer detection rate was four-fold that of England's standard screening alone.
- 2026-02-04 · England's National Cancer Plan (4 February 2026) premised its survival ambition on raising the share of cancers diagnosed at stage 1–2 by at…
2026-02-03 · policy · ●●● · published 2026-02-03verified
On 3 February 2026 the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act was signed into law as part of the FY2026 spending package, establishing Medicare coverage of FDA-approved multi-cancer early detection screening tests (one per beneficiary per year) beginning in 2028, with payment at parity with multi-target stool DNA tests through 2030.
- 2026-01-29 · An NIH-funded retrospective study published in Clinical Cancer Research on 29 January 2026 found that adding the proteins ANPEP and PIGR to …
- 2026-01-29 · Final results of the Swedish MASAI randomised trial (over 100,000 women), published in The Lancet on 29 January 2026, found AI-supported mam…
2026-01-29 · announcement · ●●○ · published 2026-01-29corrected
On 29 January 2026 GRAIL announced it had submitted the final module of its FDA premarket approval (PMA) application for the Galleri multi-cancer early detection blood test, focused on test performance and safety results from 25,490 PATHFINDER 2 participants with one year of follow-up and from the prevalent (first-year) screening round of the NHS-Galleri trial.
2026-01-12 · achievement · ●●○ · published 2026-01-12corrected
On 12 January 2026 Sanofi announced European Commission approval of Teizeild (teplizumab) to delay onset of stage 3 type 1 diabetes in patients aged 8+ with presymptomatic stage 2 disease, the first EU disease-modifying therapy for type 1 diabetes, based on the TN-10 trial in which median time to stage 3 diagnosis was 48.4 months versus 24.4 months with placebo.
2025 · projection · ●●○ · published 2026-01-04corrected
The NHS-Galleri trial is a randomised controlled trial of 140,000 participants in the NHS in England.
↳ corrects (or adds sources to) an earlier record: 2025: The NHS-Galleri trial of multi-cancer early detection enrolled 140,000 participants,…
2025 · data · ●○○ · published 2026-01-04legacy
The FDA's list of AI-enabled medical devices included 873 cleared AI radiology devices in 2025, 115 of them added in 2025.
2025-10-17 · achievement · ●●● · published 2025-10-17corrected
GRAIL reported that PATHFINDER 2 found adding Galleri to USPSTF A and B recommended screenings increased cancer detection more than seven-fold, 53.5% of new cancers detected were stage I or II, and episode sensitivity was 73.7% for the 12 cancers responsible for two-thirds of U.S. cancer deaths.
↳ corrects (or adds sources to) an earlier record: 2025-10-17: On 17 October 2025 GRAIL presented full PATHFINDER 2 results at ESMO: adding the…
2025-10-13 · achievement · ●●○ · published 2025-10-13verified
On 13 October 2025 the FDA cleared Roche's Elecsys pTau181, the first blood test for use in primary care to rule out Alzheimer's-related amyloid pathology.
↳ corrects (or adds sources to) an earlier record: 2025-10-13: On 13 October 2025 the FDA cleared Roche's Elecsys pTau181, the first blood test for…
2025-09 · achievement · ●●○ · published 2026-01-04legacy
In September 2025 Exact Sciences commercially launched Cancerguard, a multi-cancer early detection blood test with 97.4% specificity, described as detecting 80%+ of cancer diagnoses.
2025-07-29 · policy · ●●○ · published 2025-07-29verified
On 29 July 2025 the Alzheimer's Association released at AAIC the first evidence-based clinical practice guideline for the use of blood-based biomarker tests for Alzheimer's disease.
↳ corrects (or adds sources to) an earlier record: 2025-07-29: On 29 July 2025 the Alzheimer's Association released at AAIC the first evidence-based…
2025-06-18 · achievement · ●●○ · published 2025-06-18corrected
On 18 June 2025 GRAIL announced positive top-line PATHFINDER 2 results; PATHFINDER 2 had substantially higher positive predictive value than PATHFINDER, while its specificity was consistent with PATHFINDER.
↳ corrects (or adds sources to) an earlier record: 2025-06-18: On 18 June 2025 GRAIL announced positive top-line results from the PATHFINDER 2…
2025-06-02 · achievement · ●●○ · published 2026-01-04corrected
On 2 June 2025 Clairity Breast received FDA De Novo authorization as the first AI-powered platform predicting five-year breast cancer risk from a standard mammogram.
↳ corrects (or adds sources to) an earlier record: 2025-06-02: On 2 June 2025 Clairity Breast received FDA De Novo authorization as the first…
2025-05 · achievement · ●●● · published 2025-05-31verified
In May 2025 the FDA cleared the first blood test for diagnosing Alzheimer's disease, Lumipulse pTau217/Aβ1-42, with 91.7% sensitivity and 97.3% specificity.
↳ corrects (or adds sources to) an earlier record: 2025-05: In May 2025 the FDA cleared the first blood test for diagnosing Alzheimer's disease,…
2026-10-14 · achievement · ●●○ · published 2026-10-14verified
Arrowhead reported on 14 October 2026 interim phase 1/2a data in healthy volunteers showing that subcutaneously injected ARO-MAPT, a tau-silencing siRNA, crossed the blood-brain barrier and reduced CSF total tau by a mean 73% at day 105 (maximum 85%) at the 12.8 mg/kg dose, supporting quarterly dosing; patient cohorts in early Alzheimer's disease are still enrolling, with data expected in 2027.
2026-10-12 · data · ●●○ · published 2026-10-12verified
A JAMA Neurology individual-participant meta-analysis of 22 population-based COSMIC cohorts (38,418 people in 18 countries or territories; published 12 October 2026) found an age- and sex-standardised all-cause dementia incidence of 9.7 per 1,000 person-years (8.3 in high-income vs 13.6 in low- and middle-income countries) and projected 24.7 million new cases in 2050 if age-specific incidence stays constant.
- 2026-09-16 · On 16 September 2026 the US House Ways and Means Committee unanimously advanced the bipartisan Alzheimer's Screening and Prevention (ASAP) A…
2026-09-10 · announcement · ●●○ · published 2026-09-10corrected
Roche's phase 3 PrevenTRON trial, whose design was first presented at AAIC in July 2026 and which had begun recruiting in the UK by 10 September 2026, will recruit 1,600 cognitively unimpaired people aged 55–80 worldwide and randomise those with high plasma p-tau217 to the brain-shuttle anti-amyloid antibody trontinemab or placebo, following them for four to six years to test prevention or delay of symptomatic Alzheimer's disease.
2026-09-03 · achievement · ●○○ · published 2026-09-03corrected
Eisai and Biogen announced on 3 September 2026 that China's NMPA had approved the lecanemab subcutaneous autoinjector (500 mg once weekly as two 250 mg injections) as an initiation treatment for early Alzheimer's disease, allowing at-home treatment in a country where Eisai estimates 17 million people had MCI or mild dementia due to Alzheimer's in 2024.
- 2026-08-24 · On 24 August 2026 the FDA cleared Roche's Elecsys pTau217 blood test, developed with Lilly, as the first single-biomarker blood test support…
- 2026-08-20 · On 20 August 2026 the FDA cleared C2N Diagnostics' mass-spectrometry PrecivityAD2 blood test (Aβ42/40 plus %p-tau217) to aid identification …
2026-07-31 · data · ●●○ · published 2026-07-31verified
A GBD 2023 analysis in The Lancet Regional Health – Europe (31 July 2026) estimated 7.76 million people with dementia in the EU-27 in 2023 (age-standardised prevalence 651.3 per 100,000, down 1.7% since 1990 while case numbers rose 88.5%), with age-specific prevalence of 17.3% in men and 21.4% in women aged 85–89 and 29.0% and 36.4% at ages 90–94.
2026-07-29 · policy · ●●○ · published 2026-07-29verified
After a fourth committee meeting on 8 July 2026, NICE paused its appraisals of lecanemab (29 July 2026) and donanemab (30 July 2026) for NHS use in England because the manufacturers and NHS England had commenced commercial discussions.
2026-07-15 · policy · ●●○ · published 2026-07-15verified
WHO published on 15 July 2026 the second edition of its guidelines on risk reduction of cognitive decline and dementia, adding recommendations to reduce air-pollution exposure and implement tailored multidomain interventions alongside physical activity, tobacco cessation, reduced alcohol and management of hypertension, diabetes and high cholesterol, stating that up to 45% of dementia risk is attributable to modifiable risk factors.
- 2026-07-15 · A JAMA study presented at AAIC on 15 July 2026, pooling 2,684 cognitively unimpaired older adults (average age about 70) from six cohorts an…
2026-07-14 · data · ●●○ · published 2026-07-24verified
Interim open-label-extension data from the Phase Ib/IIa Brainshuttle AD study, presented at AAIC on 14 July 2026, showed that the transferrin-receptor-shuttled anti-amyloid antibody trontinemab cleared amyloid in participants switching from placebo and lowered it by a further 12 centiloids in prior high-dose recipients (92% of whom had already reached full clearance), with only two asymptomatic, radiographically mild ARIA-E cases in the extension.
2026-07-14 · data · ●●○ · published 2026-07-14verified
Full phase 2 CELIA data presented at AAIC on 14 July 2026 showed that diranersen 60 mg intrathecally every six months (n=60) slowed decline versus placebo at 18 months by 26% on CDR-SB, 42% on ADAS-Cog13 and 50% on MMSE, with 50–65% mean reductions in CSF total tau and lower tau-PET signal across doses, but no separation on the ADCS-ADL-MCI daily-function scale; Biogen plans phase 3.
2026-07-13 · announcement · ●●○ · published 2026-07-13verified
The Alzheimer's Association announced at AAIC 2026 on 13 July 2026 PROTECT-Cog, a $100 million global prevention trial testing whether adding a metabolism-targeting drug such as a GLP-1 agonist to the U.S. POINTER multidomain lifestyle intervention further protects cognition in at-risk older adults, with three years of follow-up (planned, not yet enrolled).
2026-07-13 · achievement · ●●○ · published 2026-07-13verified
The two-year randomized LatAm-FINGERS trial (1,065 at-risk older adults at 12 sites in 11 Latin American countries), reported at AAIC 2026 and in The Lancet, found that a structured, coached multidomain lifestyle intervention produced a 55% greater improvement in a global cognition composite than a self-guided programme (a cognitive-score outcome, not dementia incidence).
2026-07-13 · achievement · ●●○ · published 2026-07-13corrected
On 13 July 2026 the FDA approved a subcutaneous starting regimen of lecanemab (Leqembi Iqlik, 500 mg once weekly), the first anti-amyloid Alzheimer's treatment that can be started with at-home self- or caregiver administration, ahead of the 24 August 2026 action date to which the FDA had extended the review in May; efficacy rested on IV trial outcomes plus equivalent exposure and amyloid reduction, not a separate outcome trial.
2026-06-24 · data · ●●○ · published 2026-06-24verified
A USC-led microsimulation based on the Health and Retirement Study, published in Alzheimer's & Dementia on 24 June 2026, estimated that 5.7 million US adults aged 51+ (95% CI 5.6–6.0 million) live with dementia in 2026, with total costs of $818 billion including quality-of-life losses, unpaid care and medical and long-term care.
2026-05-14 · data · ●●○ · published 2026-05-14verified
Biogen reported on 14 May 2026 that its tau-lowering antisense drug diranersen (BIIB080) missed the primary CDR-SB dose-response endpoint of the 416-participant phase 2 CELIA trial in early Alzheimer's disease, but showed prespecified cognitive slowing across doses and reductions in CSF tau and tau-PET pathology, and that it plans to advance diranersen to registrational development.
2026-04-30 · achievement · ●○○ · published 2026-04-30corrected
On 30 April 2026 the FDA approved an expanded use of Auvelity (dextromethorphan-bupropion) extended-release tablets to treat agitation associated with dementia due to Alzheimer's disease in adults, the first FDA-approved treatment for this condition that is not an antipsychotic, based on two randomized trials (a five-week placebo-controlled trial on the Cohen-Mansfield Agitation Inventory and a randomized withdrawal trial on time to relapse).
2026-04-28 · data · ●●○ · published 2026-04-28verified
An observational matched-cohort study of US Medicare beneficiaries aged 65+ (502,845 two-dose recombinant zoster vaccine recipients vs 1,005,690 unvaccinated comparators), published in Alzheimer's & Dementia, found a lower risk of new-onset dementia after vaccination, with hazard ratios of 0.67 (95% CI 0.65–0.68) through 3 years and 0.74 (0.69–0.79) after 3 years.
2026-04-21 · data · ●●○ · published 2026-04-21verified
The Alzheimer's Association's 2026 Alzheimer's Disease Facts and Figures (21 April 2026) estimates 7.4 million Americans aged 65+ live with clinical Alzheimer's dementia (not all-cause dementia), with prevalence of 5.2% at ages 65–74, 13.8% at 75–84 and 35.8% at 85+, and projects up to 13.8 million by 2060.
2026-04-03 · policy · ●○○ · published 2026-04-03corrected
The US President's FY2027 budget request, released 3 April 2026, proposed $4,216.8 million for the National Institute on Aging, a 6.9% ($312.2 million) cut from the FY2026 enacted level of $4,528.9 million, within a $5 billion cut that would bring the NIH to $41 billion.
2026-03-25 · setback · ●●○ · published 2026-03-27verified
On 25 March 2026 Anavex withdrew its EU marketing authorisation application for blarcamesine in Alzheimer's disease before EMA completed re-examination of its December 2025 recommendation to refuse approval, which had found that the main study failed to demonstrate effectiveness.
2026-03-20 · policy · ●●○ · published 2026-03-20corrected
On 20 March 2026 NICE published appeal panel decisions upholding parts of Eisai's and Lilly's appeals against its final draft guidance (its third rejection, in June 2025) of lecanemab and donanemab for NHS use in England, remitting both appraisals to the committee to reconsider carer utility values (and, for donanemab, unpaid care costs and the EAG's critique of long-term data) and to give stakeholders adequate time to respond to NHS England's infusion cost estimates, leading to a third draft-guidance consultation from 31 March to 28 April 2026.
2026-03-19 · data · ●○○ · published 2026-03-19verified
Full evoke and evoke+ phase 3 results published in The Lancet (3,808 randomised participants with early Alzheimer's disease) confirmed that oral semaglutide up to 14 mg daily did not slow progression: CDR-SB change at week 104 differed from placebo by −0.08 (95% CI −0.35 to 0.20) in evoke and 0.10 (−0.17 to 0.38) in evoke+.
- 2026-02-19 · A Nature Medicine study published 19 February 2026 (603 older adults in the Knight ADRC and ADNI cohorts) showed that the estimated age at p…
2026-02-09 · data · ●●○ · published 2026-02-09corrected
A 20-year follow-up of the NIH-funded ACTIVE randomized trial (Medicare claims 1999–2019 for 2,021 participants aged 65+ at enrolment), published in Alzheimer's & Dementia: TRCI on 9 February 2026, found that only participants randomized to adaptive speed-of-processing training who completed booster sessions had a lower risk of claims-diagnosed dementia (HR 0.75, 95% CI 0.59–0.95; a 25% lower rate), while memory and reasoning training showed no effect.
2026-02-03 · policy · ●●○ · published 2026-02-03verified
The US FY2026 spending package signed on 3 February 2026 added $100 million for Alzheimer's and dementia research at the NIH, bringing total annual federal investment in Alzheimer's and dementia research to approximately $3.9 billion, and included $41.5 million for the CDC's BOLD Infrastructure for Alzheimer's Act programme.
2026-01-27 · achievement · ●●○ · published 2026-01-27verified
A randomized crossover trial in 39 healthy older adults, published in Nature Communications on 27 January 2026, found that glymphatic clearance during normal sleep raised morning plasma levels of amyloid-β and tau compared with sleep deprivation, indicating that the glymphatic system clears these Alzheimer's proteins from the human brain to the blood, which had previously been shown only in animal models.
2026-01-05 · achievement · ●●○ · published 2026-01-05verified
A Nature Medicine study published on 5 January 2026 (DROP-AD, 337 participants from 7 centres) found that p-tau217 measured in finger-prick capillary dried plasma spots correlated with venous plasma p-tau217 (Spearman r = 0.74) and predicted CSF Alzheimer's biomarker positivity with an area under the curve of 0.864, opening a route to remote, minimally invasive Alzheimer's blood-biomarker sampling.
2025 · data · ●○○ · published 2026-01-04corrected
According to the NHS, 1 in every 6 people over the age of 80 have Alzheimer’s disease.
↳ corrects (or adds sources to) an earlier record: 2025: According to the NHS, about 1 in 6 (~17%) people aged over 80 in the UK have dementia.
2025 · achievement · ●●○ · published 2026-01-04verified
Eisai's anti-tau antibody etalanetug reduced plasma eMTBR-tau243 by more than 90% at 9 months and received FDA Fast Track designation.
↳ corrects (or adds sources to) an earlier record: 2025: Eisai's anti-tau antibody etalanetug reduced plasma eMTBR-tau243 by more than 90% at 9…
2025 · data · ●●○ · published 2026-01-04corrected
The US ADAMS study estimated dementia prevalence at 24.19% among people aged 80–89 and 37.36% among those aged 90 and older.
↳ corrects (or adds sources to) an earlier record: 2025: The US ADAMS study estimated dementia prevalence at about 24% among people aged 80–89…
2025-12 · analysis · ●●○ · published 2025-12-31corrected
Eisai reported that modeling estimated continued lecanemab treatment could delay progression from MCI due to Alzheimer’s disease to moderate disease by 3.5 years overall and 8.3 years in the low-amyloid group.
↳ corrects (or adds sources to) an earlier record: 2025-12: Eisai reported at CTAD in December 2025 that continued lecanemab treatment may delay…
2025 · achievement · ●●○ · published 2025-04-21verified
A 2025 Nature Medicine study in 33,995 Chinese adults found intensive blood pressure control reduced dementia risk by 15% (RR 0.85) over 4 years.
↳ corrects (or adds sources to) an earlier record: 2025: A 2025 Nature Medicine study in 33,995 Chinese adults found intensive blood pressure…
2025-11-24 · setback · ●●● · published 2025-11-24verified
On 24 November 2025 oral semaglutide failed the Phase 3 evoke and evoke+ trials, showing no slowing of Alzheimer's disease progression.
↳ corrects (or adds sources to) an earlier record: 2025-11-24: On 24 November 2025 oral semaglutide failed the Phase 3 evoke and evoke+ trials,…
2025-11-21 · setback · ●●○ · published 2026-01-04corrected
On November 21, 2025, Johnson & Johnson announced that posdinemab did not achieve statistical significance in slowing clinical decline in the Auτonomy study, which it would discontinue.
↳ corrects (or adds sources to) an earlier record: 2025-11-25: On 25 November 2025 J&J's anti-tau antibody posdinemab failed its pivotal Alzheimer's…
- 2025-10-13 · On 13 October 2025 the FDA cleared Roche's Elecsys pTau181, the first blood test for use in primary care to rule out Alzheimer's-related amy…
2025-08-28 · setback · ●●○ · published 2025-08-28corrected
On 28 August 2025 the FDA recommended an additional, earlier MRI monitoring prior to the 3rd infusion for Alzheimer's patients taking Leqembi (lecanemab) after identifying six fatal ARIA-E cases early in treatment.
↳ corrects (or adds sources to) an earlier record: 2025-08-28: On 28 August 2025 the FDA recommended additional, earlier MRI monitoring for…
2025-07-30 · achievement · ●●○ · published 2025-07-30corrected
On 30 July 2025 Lilly reported three-year TRAILBLAZER-ALZ 2 data: CDR-SB decline was reduced by 1.2 points at 36 months versus the matched ADNI group, and earlier Kisunla initiation reduced progression to the next disease stage by 27% on CDR-G versus delayed initiation.
↳ corrects (or adds sources to) an earlier record: 2025-07-30: On 30 July 2025 Lilly reported 3-year TRAILBLAZER data for Kisunla (donanemab) showing…
- 2025-07-29 · On 29 July 2025 the Alzheimer's Association released at AAIC the first evidence-based clinical practice guideline for the use of blood-based…
- 2025-05 · In May 2025 the FDA cleared the first blood test for diagnosing Alzheimer's disease, Lumipulse pTau217/Aβ1-42, with 91.7% sensitivity and 97…
2025-01 · policy · ●○○ · published 2026-01-04corrected
In January 2025 the FDA approved once-every-four-weeks intravenous maintenance dosing of lecanemab for early Alzheimer's disease.
↳ corrects (or adds sources to) an earlier record: 2025-01-26: On 26 January 2025 the FDA approved intravenous maintenance dosing every 4 weeks for…
2024 · analysis · ●●○ · published 2024-12-31legacy
The 2024 Lancet Commission on dementia reported that age-standardized dementia incidence has declined by about 20% in high-income countries over 2–3 decades, attributed to better cardiovascular health and education, while absolute case numbers grow with population aging.
2022 · data · ●○○ · published 2026-01-04verified
The SHARE 2022 study found dementia prevalence among people aged 65+ in Europe ranging from 4.5% to 22.7% depending on the country.
↳ corrects (or adds sources to) an earlier record: 2022: The SHARE 2022 study found dementia prevalence among people aged 65+ in Europe ranging…
2026-10-14 · achievement · ●●○ · published 2026-10-14verified
A Wyss Institute/Church-lab study published in Nature Aging on 14 October 2026 used a transcriptomic-age screen in old human fibroblasts to identify the splicing factor SRSF1, whose overexpression reversed several aging hallmarks without loss of fibroblast identity or pluripotency-program activation, and whose liver-tropic AAV delivery to aged mice slowed frailty and extended median lifespan by 14% versus controls.
2026-10-12 · data · ●●○ · published 2026-10-12verified
Rubedo Life Sciences reported on 12 October 2026 that four weeks of topical RLS-1496 in its Phase 1b atopic dermatitis study reduced measured skin epigenetic age (MitraBio clock) by a mean 2.1 years across 11 paired photo-aged skin samples (p=0.032), and that final Phase 1b/2a data in 22 actinic keratosis patients showed a mean 49% lesion reduction after 28 days with minimal irritation.
2026-10-08 · data · ●●○ · published 2026-10-08verified
On 8 October 2026 Life Biosciences reported interim Phase 1 data showing that a single intravitreal Dose Level 1 of the OSK reprogramming therapy ER-100 with 56 days of oral doxycycline was well tolerated through Day 56 in 3 open-angle glaucoma participants with no dose-limiting toxicities or serious adverse events, with visual-field improvements in 2 of 3 and a recommendation to escalate to Dose Level 2.
2026-10-01 · policy · ●●○ · published 2026-10-02corrected
At ARDD 2026 on 1 October 2026 FDA Chief Scientist Steven Kozlowski said the agency plans to include aging and longevity among the topics of its updated Focus Areas of Regulatory Science report due early in fiscal year 2027, while FDA's Jeffrey Siegel described benefit across two or three age-related diseases sharing a mechanism as one possible approval route for aging therapies.
2026-10-01 · data · ●●○ · published 2026-10-01corrected
A double-blind randomized proof-of-principle trial of the senolytics dasatinib plus quercetin in 31 patients with biopsy-proven fibrotic MASH (21 weeks; Nature Metabolism, 1 October 2026) met its primary endpoint, with ≥1-point fibrosis improvement without MASH worsening in 8 of 17 (47%) D+Q participants versus 1 of 14 (7%) on placebo.
2026-09-30 · announcement · ●○○ · published 2026-09-30corrected
On 30 September 2026 the KHL Foundation disclosed that a small number of people had received an experimental 11-gene therapy containing the OSK reprogramming factors, developed through a Triple Helix Science initiative, one of them dosed submucosally on 11 March 2026 (before Life Biosciences' 9 June 2026 announcement of the first participant dosed in its ER-100 trial), while stating that this did not prove OSK reverses cognitive decline.
2026-09-22 · data · ●●○ · published 2026-09-22corrected
A Novo Nordisk-coauthored preprint posted on 22 September 2026 analyzing proteomics from 10,052 participants in five placebo-controlled semaglutide trials (up to 156 weeks) reported that semaglutide reduced proteomic heart biological age by about 2-4 years versus placebo and kidney, brain, pancreas, lung and multi-organ clock ages by 1-4 years, while the authors stated this does not establish biological rejuvenation or surrogate validity.
2026-09-07 · data · ●●○ · published 2026-09-07corrected
A Nature Biotechnology analysis published on 7 September 2026 of serum proteomics from 42 idiopathic pulmonary fibrosis patients in Insilico's randomized placebo-controlled 12-week phase 2a trial of rentosertib found all six proteomic aging clocks trending toward lower predicted biological age, which Insilico put at about 3–4 years (up to 6 years on one clock) at week 4 in the 30 mg twice-daily group.
2026-09-02 · achievement · ●●● · published 2026-09-02verified
A Nature study published on 2 September 2026 found that daily semaglutide started in 20-month-old female C57BL/6 mice improved physical and cognitive function, attenuated hallmarks of ageing including inflammation, senescence and stem-cell decline, and, continued for life, extended lifespan by about 100 days on average versus vehicle, acting as a calorie-restriction mimetic with some benefits beyond matched 24% calorie restriction.
2026-08-21 · analysis · ●●○ · published 2026-08-21verified
A Nature Medicine study published on 21 August 2026 harmonized 51 human intervention studies with DNA-methylation data (TranslAGE) and computed 16 epigenetic clocks plus 94 other DNAm biomarkers, finding DunedinPACE showed the largest effect sizes and PCGrimAge the most significant results, with pharmacological interventions producing larger effects than lifestyle, supplement or procedure interventions.
2026-08-11 · announcement · ●●○ · published 2026-08-11verified
On 11 August 2026 XPRIZE named 20 finalist teams in the $101 million XPRIZE Healthspan, ten of which received $1 million Milestone 2 awards ($10 million in total), to run clinical trials of up to one year in 2026-2029 aiming to restore muscle, cognitive and immune function by at least 10 years in adults aged 50-90, with a grand prize of up to $81 million in 2030.
2026-07-28 · data · ●●○ · published 2026-07-28verified
A medRxiv preprint posted on 28 July 2026 reported a 2-year double-blind randomized trial of metformin versus placebo in 145 non-frail or pre-frail adults (mean age 72) with glucose intolerance, in which metformin improved the frailty index (−0.006 per year vs placebo) but not the Fried phenotype and reduced biological age by 0.40 years per year on PC-Horvath2 and 0.33 years per year on PC-Hannum.
2026-07-25 · policy · ●○○ · published 2026-07-30verified
Montana's rules implementing its expanded right-to-try law took effect on 25 July 2026, letting companies whose drugs have passed preliminary testing pay $12,500 to apply to an experimental treatment review board and then sell unapproved drugs, including candidate longevity therapies, to any consenting patient through experimental treatment clinics.
2026-06-15 · achievement · ●●○ · published 2026-06-15verified
A Nature Medicine study published on 15 June 2026 used over 7,000 plasma proteins in 60,542 people to build biological-age estimates for more than 40 cell types that predicted incident disease and mortality over 15 years of follow-up, finding for example that extreme astrocyte aging tripled Alzheimer's risk in APOE4 homozygotes and extremely aged skeletal myocytes carried a 12.7-fold higher risk of ALS.
2026-06-09 · achievement · ●●● · published 2026-06-09corrected
On 9 June 2026 Life Biosciences announced that the first participant had been dosed in its Phase 1 trial of ER-100 (NCT07290244), an OSK (OCT4, SOX2, KLF4) epigenetic reprogramming therapy for optic neuropathies including open-angle glaucoma and NAION.
2026-06-02 · achievement · ●●○ · published 2026-06-02verified
A Nature Aging study published on 2 June 2026 in 264 male and 264 female C57BL/6J mice on regular chow found that nightly time-restricted feeding extended a composite healthspan index in both sexes, while 8-hour feeding extended median lifespan by about 12% (to 916 days) only in males, with no significant lifespan extension in females.
2026-06-02 · announcement · ●●○ · published 2026-06-02verified
On 2 June 2026 epigenetic reprogramming company NewLimit closed a $435 million Series C led by Founders Fund and said it plans to bring its first aging reprogramming medicine, a liver therapy, into human clinical trials in 2027.
2026-05-22 · announcement · ●●○ · published 2026-05-22verified
On 22 May 2026 Retro Biosciences announced the initial close of a financing round led by 4P Capital at a $1.8 billion pre-money valuation (amount undisclosed), with its autophagy drug RTR242 in a Phase I trial and further first-in-human milestones planned for 2026 and 2027.
2026-05-19 · data · ●●○ · published 2026-05-19verified
A post hoc analysis of a 32-week randomized placebo-controlled phase 2b trial in HIV-associated lipohypertrophy, published in Nature Communications on 19 May 2026 (84 participants with clock data), found semaglutide associated with a 0.09 lower DunedinPACE pace of aging (about 9% slower) and a PhenoAge reduction of 4.90 years per year relative to placebo.
2026-05-18 · policy · ●○○ · published 2026-05-18corrected
An ARPA-H-convened working group issued a consensus statement to the FDA, dated 18 May 2026, recommending how intrinsic capacity across five domains (locomotor, cognitive, psychological, sensory, vitality) could be measured and used as clinical endpoints and enrichment tools in geroscience/healthspan trials, while explicitly not claiming that intrinsic capacity is a validated surrogate endpoint for mortality or disability.
2026-04-15 · setback · ●●○ · published 2026-04-15corrected
The RAPA-EX-01 randomised double-blind trial in 40 sedentary adults aged 65–85 (Journal of Cachexia, Sarcopenia and Muscle, 15 April 2026) found that once-weekly 6 mg sirolimus (rapamycin) for 13 weeks did not enhance gains from home exercise: chair-stand improvement was 2.13 repetitions lower than placebo in the primary analysis (p = 0.089) and 3.44 lower per protocol (p = 0.007), with more adverse events (99 vs 63) and one possibly drug-related pneumonia.
2026-04-08 · announcement · ●○○ · published 2026-04-08verified
On 8 April 2026 Life Biosciences closed a fully subscribed $80 million financing to fund operations into the second half of 2027, including completion of its recently initiated Phase 1 trial of the partial epigenetic reprogramming therapy ER-100.
2026-03-30 · announcement · ●●○ · published 2026-03-30verified
On 30 March 2026 the University of Arizona announced a $12 million philanthropically funded double-blind randomized Phase 3 trial of low-dose rapamycin versus placebo for two years (plus one year of follow-up) in adults aged 65 and older, with transition to frailty and blood IL-6 as main outcomes, projected to take six years pending final FDA approval.
2026-03-17 · setback · ●●○ · published 2026-03-17verified
The NIA Interventions Testing Program reported in GeroScience on 17 March 2026 that none of 11 regimens tested in its C2022 cohort of genetically heterogeneous UM-HET3 mice (including astaxanthin, meclizine and mitoglitazone at new doses or start ages, pioglitazone, alpha-ketoglutarate, mifepristone, methotrexate and atorvastatin-telmisartan) increased lifespan in either sex, and that pioglitazone reduced female median lifespan by 6.2%.
2026-03-09 · data · ●●○ · published 2026-03-09corrected
A prespecified ancillary study of the COSMOS randomized trial (958 participants, 2 years; Nature Medicine, 9 March 2026) found that a daily multivitamin modestly slowed second-generation epigenetic clocks versus placebo, by 0.113 years per year on PCGrimAge and 0.214 years per year on PCPhenoAge, while cocoa extract had no effect.
2026-02-25 · data · ●○○ · published 2026-02-25verified
Longeveron's Phase 2b trial of allogeneic bone-marrow MSCs (laromestrocel) in 148 ambulatory adults with aging frailty, published in Cell Stem Cell on 25 February 2026, reported a 63.4 m improvement in 6-minute walk distance versus placebo at month 9 (p=0.0077) and a non-significant 41.3 m at month 6 (p=0.0635).
2026-02-24 · announcement · ●●○ · published 2026-02-24corrected
On 24 February 2026 ARPA-H announced the seven performer teams of its PROSPR healthspan programme, investing up to $144 million over five years to identify early biomarkers of aging usable as surrogate endpoints and to run the first trials aimed at extending healthspan, including a UT Health San Antonio phase 3 hybrid trial repurposing an SGLT2 inhibitor, rapamycin and semaglutide to establish a regulatory path for aging therapeutics.
2026-01-28 · achievement · ●●○ · published 2026-01-28corrected
On 28 January 2026 Life Biosciences announced that the US FDA had cleared its IND for ER-100, a therapy based on controlled expression of the OCT4, SOX2 and KLF4 (OSK) reprogramming factors, allowing a Phase 1 first-in-human trial (NCT07290244) in open-angle glaucoma and NAION, which the company called the first cellular rejuvenation therapy using partial epigenetic reprogramming to reach human clinical trials.
2026-01-13 · achievement · ●●○ · published 2026-01-13corrected
On 13 January 2026 Loyal announced that the FDA Center for Veterinary Medicine had accepted the Target Animal Safety section of its expanded conditional approval application for LOY-002, a metabolic-dysfunction drug intended to extend healthy lifespan in senior dogs, based on data from over 400 dogs given the drug, completing two of the three major technical sections (after effectiveness was accepted in February 2025) with only manufacturing remaining.
2025 · achievement · ●●○ · published 2025-12-31corrected
In 2025, Retro Biosciences dosed the first participant in a clinical trial of its autophagy-focused drug candidate RTR242, becoming a clinical-stage company.
↳ corrects (or adds sources to) an earlier record: 2025-12: In December 2025 Retro Biosciences dosed the first patient in a trial of RTR242, an…
2025 · achievement · ●●○ · published 2025-12-31corrected
A 2025 study reported that rapamycin combined with trametinib extended mouse lifespan by around 30%.
↳ corrects (or adds sources to) an earlier record: 2025: A 2025 Nature Aging preclinical study found that rapamycin combined with trametinib…
2025 · analysis · ●●○ · published 2025-12-31corrected
The 2025 review reported that early rapamycin-plus-acarbose treatment extended lifespan by 28% in female mice and 37% in male mice, while canagliflozin extended median lifespan by 14% in male mice.
↳ corrects (or adds sources to) an earlier record: 2025: A 2025 Journal of Gerontology 20-year review of the NIA Interventions Testing Program…
2025-11 · data · ●●○ · published 2025-11-30verified
Phase IIb data reported in November 2025 showed concordant decreases in 11 organ-system epigenetic clocks with semaglutide treatment.
↳ corrects (or adds sources to) an earlier record: 2025-11: Phase IIb data reported in November 2025 showed concordant decreases in 11 organ-system…
2025-09 · setback · ●●○ · published 2025-12-31corrected
UNITY Biotechnologies ceased operations following a clinical trial that was not impressive enough for the company to continue operating.
↳ corrects (or adds sources to) an earlier record: 2025-09: In September 2025 UNITY Biotechnology's liquidation was approved after its Phase 2b…
2025-08 · announcement · ●●○ · published 2025-08-31corrected
In August 2025 Life Biosciences announced that ER-100, its partial epigenetic reprogramming therapy, was on track to enter human trials in the first quarter of 2026.
↳ corrects (or adds sources to) an earlier record: 2025-08: In August 2025 Life Biosciences announced that ER-100, its partial epigenetic…
2025-08-22 · achievement · ●●● · published 2025-08-22corrected
OpenAI and Retro Biosciences reported that GPT‑4b micro-designed SOX2 variants achieved greater than 50-fold higher expression of stem cell reprogramming markers than wild-type controls, while 14 model-generated KLF4 variants had a nearly 50% hit rate and the variants enhanced DNA damage repair.
↳ corrects (or adds sources to) an earlier record: 2025-08-22: On 22 August 2025 OpenAI and Retro Biosciences reported that SOX2 and KLF4…
2025-06 · achievement · ●●○ · published 2025-06-30corrected
The bioRxiv preprint reported a 7.42-year decline in PCHorvath2013 epigenetic age in SB000-treated fibroblasts.
↳ corrects (or adds sources to) an earlier record: 2025-06: A June 2025 bioRxiv preprint reported that SB000, a novel and potentially safer…
2025-05 · achievement · ●●○ · published 2025-05-31corrected
In May 2025 a Buck Institute-led trial reported that biweekly therapeutic plasma exchange with IVIG reduced biological age by an average of 2.61 years.
↳ corrects (or adds sources to) an earlier record: 2025-05: In May 2025 a Buck Institute randomized trial of therapeutic plasma exchange plus IVIG…
2021 · data · ●○○ · published 2021-12-31corrected
A 2021 randomized controlled clinical trial found that an 8-week diet and lifestyle treatment group scored 3.23 years younger than controls on the Horvath DNAmAge clock.
↳ corrects (or adds sources to) an earlier record: 2021: A 2021 randomized controlled trial (Fitzgerald et al., Aging) of an 8-week diet and…
2019 · data · ●○○ · published 2019-12-31legacy
The 2019 TRIIM trial (rhGH + metformin + DHEA) in 9 participants reported a 2.5-year reversal of biological age across 4 epigenetic clocks.
- 2026-10-14 · Arrowhead reported on 14 October 2026 interim phase 1/2a data in healthy volunteers showing that subcutaneously injected ARO-MAPT, a tau-sil…
2026-09-29 · data · ●●○ · published 2026-09-29corrected
uniQure reported on 29 September 2026 that versus an updated propensity-matched external control, high-dose AMT-130 slowed Huntington's disease progression at 36 months by 80% on cUHDRS (n=15, nominal p=0.005) and 67% on Total Functional Capacity, and at 48 months by 44% on cUHDRS (n=12, not significant, p=0.144) and 61% on TFC (nominal p=0.008), with 5 of the high-dose participants (17%) having had resolved treatment-related CNS-inflammation serious adverse events.
2026-09-22 · achievement · ●●○ · published 2026-09-22corrected
Ionis and Otsuka announced on 22 September 2026 that the Phase 3 FUSION trial of ulefnersen, an intrathecally administered RNA-targeted medicine designed to reduce FUS protein production, met its primary endpoint in people with FUS-ALS (primary analysis population N=73), a statistically significant improvement on a 72-week joint rank of ALSFRS-R function, time to rescue and ventilation-assistance-free survival, with a statistically significant improvement in serum neurofilament light chain, making it the first FUS-ALS trial to meet its primary endpoint.
2026-09-03 · achievement · ●●○ · published 2026-09-03corrected
On 3 September 2026 the FDA approved Ionis's Zanvastro (zilganersen), an intrathecal antisense oligonucleotide that reduces production of the abnormal GFAP protein, as the first treatment for Alexander disease and the first therapy to directly target the protein buildup that drives it, based on a 49-patient randomized controlled study in which treated patients aged 5+ with walking difficulty at baseline had significantly better walking speed at 61 weeks than untreated controls.
2026-09-02 · announcement · ●●○ · published 2026-09-02corrected
uniQure announced on 2 September 2026 that it had submitted a BLA to the FDA for accelerated approval and a Marketing Authorisation Application to the UK MHRA for ifezuntirgene inilparvovec (AMT-130) for Huntington's disease, a one-time striatal huntingtin-silencing gene therapy, based on 3-year Phase I/II data versus a propensity score-matched external control.
- 2026-07-23 · An NIH-funded Science study published on 23 July 2026, profiling hippocampi from 40 neurologically healthy adults aged 20–95, found that bet…
- 2026-07-14 · Interim open-label-extension data from the Phase Ib/IIa Brainshuttle AD study, presented at AAIC on 14 July 2026, showed that the transferri…
- 2026-07-14 · Full phase 2 CELIA data presented at AAIC on 14 July 2026 showed that diranersen 60 mg intrathecally every six months (n=60) slowed decline …
2026-07-09 · achievement · ●●○ · published 2026-07-09corrected
The Phase 1/2 STEM-PD trial, published in Nature Medicine on 9 July 2026, reported 12-month primary safety endpoint results for bilateral putaminal transplantation of an off-the-shelf human embryonic stem cell-derived dopaminergic progenitor product in 8 people with moderate Parkinson's disease: no serious adverse events attributed to the cells, no graft-induced dyskinesias and no tumour formation on MRI, though one participant died 10 weeks after transplantation of a fungal pulmonary infection acquired on active immunosuppression.
2026-07-09 · setback · ●●○ · published 2026-07-09corrected
Roche told the Huntington's disease community on 9 July 2026 that it was discontinuing tominersen, a huntingtin-lowering drug given by spinal fluid injection, after the 301-participant Phase II GENERATION HD2 trial significantly lowered mutant huntingtin and NfL but had no meaningful clinical efficacy over its 16-month treatment period, and was also stopping its Phase I POINT-HD study of the mutant-allele-selective RG6496 after non-clinical data showed it cannot be given chronically with repeated doses.
2026-06-17 · policy · ●●○ · published 2026-06-17corrected
uniQure announced on 17 June 2026 that after a recent Type B meeting the FDA communicated, reversing its March 2026 position, that the 3-year Phase I/II analysis of AMT-130 compared with a propensity score-matched external control would be acceptable as the primary basis of a BLA for accelerated approval in Huntington's disease, with the FDA seeking to align on the confirmatory study design before submission and a BLA planned for Q3 2026.
2026-05-21 · setback · ●●○ · published 2026-05-21verified
Biogen and Denali announced on 21 May 2026 that the 648-participant Phase 2b LUMA trial of the LRRK2 kinase inhibitor BIIB122 (DNL151) in early-stage Parkinson's disease missed its primary and secondary endpoints, and discontinued its development in idiopathic Parkinson's disease.
- 2026-05-14 · Biogen reported on 14 May 2026 that its tau-lowering antisense drug diranersen (BIIB080) missed the primary CDR-SB dose-response endpoint of…
2026-04-28 · data · ●●○ · published 2026-04-28corrected
PTC Therapeutics reported on 28 April 2026 that in the 24-month interim analysis of the PIVOT-HD extension, the small-molecule huntingtin-lowering splicing modifier votoplam slowed progression on the composite UHDRS in Stage 2 Huntington's disease by 52% (10 mg) and 28% (5 mg) versus a propensity-weighted external natural-history cohort, and that Novartis had started the ~770-patient placebo-controlled Phase 3 INVEST-HD trial.
2026-03-25 · achievement · ●●● · published 2026-03-25verified
On 25 March 2026 the FDA granted accelerated approval to Denali's Avlayah (tividenofusp alfa), an enzyme fused to a transferrin-receptor-binding TransportVehicle, for neurologic manifestations of Hunter syndrome, the first FDA-approved biologic engineered to cross the blood-brain barrier, based on a 91% mean reduction in cerebrospinal-fluid heparan sulfate at week 24 in a 47-patient phase 1/2 trial.
- 2026-03-18 · Aspen Neuroscience reported at AD/PD 2026 on 18 March 2026 that 12 months after bilateral putaminal transplantation of sasineprocel (ANPD001…
- 2026-03-11 · A Nature study published on 11 March 2026 reported in mice that age-related accumulation of medium-chain-fatty-acid-producing gut bacteria s…
2026-03-11 · achievement · ●●○ · published 2026-03-11corrected
A medRxiv preprint posted on 11 March 2026 reported two crossover trials in healthy adults aged 55–64: dexmedetomidine alone failed to increase plasma clearance indices, while in the second trial (22 enrolled) ACX-02 (intravenous dexmedetomidine plus 10 mg oral midodrine) increased EEG slow waves and cerebrovascular pulsatility and reduced brain parenchymal resistance, raising plasma indices of amyloid-β and tau clearance from the brain by about 9–10% during a single 4h15min sleep opportunity, which the authors present as the first demonstration of pharmacological enhancement of glymphatic clearance in humans (not peer reviewed).
- 2026-03-06 · On 6 March 2026 Japan's MHLW granted conditional, time-limited approval to Sumitomo Pharma's allogeneic iPS cell-derived dopaminergic neural…
2026-03-03 · achievement · ●●○ · published 2026-03-03verified
A PNAS study published on 3 March 2026 reported short-term functional recovery of the adult mouse hippocampus after cryopreservation by vitrification, both of brain slices and of the whole brain in situ, with preserved structural integrity, metabolic responsiveness, neuronal excitability, synaptic transmission and long-term potentiation (the cellular basis of learning and memory).
2026-03-02 · setback · ●●○ · published 2026-03-02corrected
uniQure announced on 2 March 2026 that the FDA, in final minutes of a 30 January 2026 Type A meeting, stated it could not agree that Phase I/II data compared with an external control are sufficient to provide the primary evidence of effectiveness for a marketing application for AMT-130, its investigational gene therapy for Huntington's disease, and strongly recommended a prospective, randomized, double-blind, sham-surgery-controlled study.
2026-02-25 · achievement · ●●○ · published 2026-02-25verified
A Nature study published on 25 February 2026 profiled 355,997 nuclei from post-mortem human hippocampi of young adults, cognitively healthy older adults, SuperAgers (80+ with memory of people in their 50s), and people with preclinical or clinical Alzheimer's disease, identifying neural stem cells, neuroblasts and immature neurons in adults, chromatin-driven dysregulation of neurogenesis beginning at the preclinical Alzheimer's stage, and a distinct neurogenesis 'resilience signature' in SuperAgers.
- 2026-02-10 · EPFL researchers reported in Neuron (February 2026) that a brief, AAV-delivered pulse of the OSK reprogramming factors targeted only to memo…
- 2026-01-27 · A randomized crossover trial in 39 healthy older adults, published in Nature Communications on 27 January 2026, found that glymphatic cleara…
- 2025 · Eisai's anti-tau antibody etalanetug reduced plasma eMTBR-tau243 by more than 90% at 9 months and received FDA Fast Track designation.
2025-12 · achievement · ●●○ · published 2025-12-09corrected
A brain-computer interface reported in Nature Electronics in December 2025 has 65,536 electrodes and a 100 Mbps wireless link, and rests on the brain like wet tissue paper.
↳ corrects (or adds sources to) an earlier record: 2025-12: A brain-computer interface reported in Nature Electronics in December 2025 has 65,000+…
2024 · achievement · ●●○ · published 2024-12-31corrected
A Nature Biotechnology study reported the BCC10 platform, enabling intravenous delivery of large therapeutic molecules across the blood-brain barrier.
↳ corrects (or adds sources to) an earlier record: 2024: A 2024 Nature Biotechnology study reported the BCC10 platform, enabling intravenous…
2024-10 · achievement · ●●○ · published 2026-01-04verified
In October 2024 a PNAS study provided the first confirmation that the brain's glymphatic waste-clearance system exists and functions in living humans.
↳ corrects (or adds sources to) an earlier record: 2024-10: In October 2024 a PNAS study provided the first confirmation that the brain's…
2026-10-15 · data · ●●○ · published 2026-10-16corrected
CDC reported 4,410 confirmed US measles cases in 2026 as of 15 October 2026, nearly double the 2,289 for the full year 2025, with 42 new outbreaks and 96% of cases outbreak-associated, ahead of PAHO's November 2026 review of US elimination status.
2026-10-06 · data · ●●● · published 2026-10-08verified
WHO's 8 October 2026 Disease Outbreak News reported that the Bundibugyo-virus Ebola outbreak in the Democratic Republic of the Congo had reached 8,728 confirmed cases and 4,205 confirmed deaths (48.2% case fatality) across 64 health zones as of 6 October 2026, with a first imported fatal case in Kenya.
2026-09-29 · data · ●●○ · published 2026-09-29verified
WHO reported on 29 September 2026 that 47 countries reported 451,499 cholera cases and 7,870 cholera deaths in 2025, deaths up 30% despite fewer cases and the highest annual total reported to WHO since 1999.
2026-09-04 · setback · ●●○ · published 2026-09-04verified
Novartis announced on 4 September 2026 that the Phase 3 Lp(a)HORIZON outcomes trial of pelacarsen in 8,323 patients with elevated lipoprotein(a) and established cardiovascular disease lowered Lp(a) but did not meet its primary endpoint of reducing major cardiovascular events.
2026-07-29 · policy · ●●○ · published 2026-07-29verified
On 29 July 2026 the US State Department and HHS said the United States would immediately release all $600 million of Congressionally appropriated FY25 and FY26 funds to Gavi after vaccine-safety commitments, while providing no US funding to WHO through Gavi.
2026-07-28 · policy · ●●○ · published 2026-07-28verified
On 28 July 2026 the US administration released a government-wide policy prohibiting federal support for dangerous gain-of-function research in the US and abroad and establishing new oversight of high-risk life sciences research.
2026-07-27 · data · ●●○ · published 2026-07-27verified
UNAIDS' special report for AIDS 2026 (27 July 2026) estimated 1.2 million new HIV infections and 570,000 AIDS-related deaths in 2025, deaths 57% below 2010, but said the world is not on track to end AIDS as a public health threat by 2030 amid declining external financing.
- 2026-07-25 · Montana's rules implementing its expanded right-to-try law took effect on 25 July 2026, letting companies whose drugs have passed preliminar…
2026-07-02 · data · ●●○ · published 2026-07-02verified
CDC's provisional 2025 mortality report (2 July 2026) estimated 3,094,593 US deaths in 2025 and a death rate of 689.2 per 100,000, a 4.6% decrease from 2024 and a record low, with heart disease (694,708) and cancer (622,832) the leading causes.
2026-05-23 · policy · ●●○ · published 2026-05-25verified
On 23 May 2026 the 79th World Health Assembly adopted the updated Global Action Plan on Antimicrobial Resistance 2026–2036, a One Health framework for the next decade succeeding the 2015 plan.
2026-05-22 · policy · ●●○ · published 2026-05-22verified
On 22 May 2026 the 79th World Health Assembly established a member-state-led, WHO-hosted joint process to reform the global health architecture, asking the Director-General for a final report with options and recommendations to the 2027 Assembly.
2026-05-21 · achievement · ●●○ · published 2026-05-21verified
Lilly reported on 21 May 2026 that in the Phase 3 TRIUMPH-1 obesity trial, participants on the triple GIP/GLP-1/glucagon agonist retatrutide 12 mg lost an average of 28.3% of body weight over 80 weeks, with 45.3% achieving at least 30% weight loss.
- 2026-05-21 · Daewoong Pharmaceutical said on 21 May 2026 that it had won a 6 May live auction for the core assets of US reprogramming company Turn Biotec…
2026-05-17 · setback · ●●● · published 2026-05-17verified
On 17 May 2026 WHO declared the Bundibugyo-virus Ebola epidemic in the Democratic Republic of the Congo and Uganda a public health emergency of international concern, with 8 laboratory-confirmed cases, 246 suspected cases and 80 suspected deaths in Ituri and two confirmed imported cases in Kampala as of 16 May; no approved vaccine or specific treatment exists for this virus.
2026-05-13 · data · ●●○ · published 2026-05-13verified
CDC provisional data (13 May 2026) estimated 69,973 US drug overdose deaths in 2025, down almost 14% from 81,313 in 2024 and the third consecutive annual decrease, with opioid-involved deaths falling from 55,296 to 44,564.
2026-05-06 · policy · ●●○ · published 2026-05-06verified
CMS announced on 6 May 2026 the Medicare GLP-1 Bridge demonstration, giving eligible Medicare Part D beneficiaries certain GLP-1 weight-loss medications for $50 per month from 1 July 2026 through 31 December 2027.
2026-05-01 · setback · ●●○ · published 2026-05-01corrected
WHO member states ended the resumed sixth IGWG session on 1 May 2026 without finalizing the Pandemic Agreement's Pathogen Access and Benefit Sharing (PABS) annex, which must be finalized before countries can proceed with signature and ratification of the Agreement; the May 2026 World Health Assembly was to be asked to continue the negotiations and receive the outcome at the May 2027 Assembly or an earlier 2026 special session.
2026-04-27 · achievement · ●●● · published 2026-04-27verified
Intellia reported on 27 April 2026 that its one-time in vivo CRISPR therapy lonvo-z met the primary endpoint of the Phase 3 HAELO trial in hereditary angioedema, reducing attacks by 87% versus placebo over weeks 5–28, and began a rolling BLA aiming for a US launch in the first half of 2027.
2026-04-23 · achievement · ●●○ · published 2026-04-23verified
On 23 April 2026 the FDA granted accelerated approval to Regeneron's Otarmeni (lunsotogene parvec), the first dual-AAV-vector gene therapy and the first gene therapy for genetic (OTOF-related) hearing loss, after 80% of 20 efficacy-evaluable patients had improved hearing.
2026-04-14 · announcement · ●●○ · published 2026-04-14verified
On 14 April 2026 the US State Department expanded its partnership with Gilead and the Global Fund to reach an additional 1 million people in high-burden countries with twice-yearly injectable lenacapavir HIV prevention, for a combined goal of 3 million people by 2028.
2026-04-13 · policy · ●●○ · published 2026-04-13corrected
The American Council on Education reported on 13 April 2026 that the administration had not sought Supreme Court review of the First Circuit's unanimous ruling affirming the block on the NIH's 15% cap on facilities and administrative (indirect) cost reimbursement, concluding the indirect-cost-cap litigation with the plaintiff associations and universities winning all four cases.
2026-04-03 · policy · ●●○ · published 2026-04-03verified
The US President's FY2027 budget request (3 April 2026) asked for $41 billion for the NIH, a $5 billion cut, and proposed reducing its institutes and centers from 27 to 22, eliminating the Fogarty International Center, NCCIH and NIMHD.
- 2026-04-03 · The US President's FY2027 budget request, released 3 April 2026, proposed $4,216.8 million for the National Institute on Aging, a 6.9% ($312…
2026-04-01 · achievement · ●●● · published 2026-04-01corrected
On 1 April 2026 the FDA approved Lilly's Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist pill for weight reduction in adults with obesity or overweight with a weight-related comorbidity, 50 days after filing, as the first new molecular entity approved under the national priority voucher pilot.
2026-03-20 · achievement · ●●○ · published 2026-03-20corrected
Novo Nordisk's semaglutide (Ozempic/Wegovy) patents expired in India on 20 March 2026 and generic launches began that day, with Natco launching multi-dose vials priced from 1,290 rupees ($13.79) per month and more than 40 generic makers expected to launch cheaper versions.
2026-03-19 · achievement · ●●○ · published 2026-03-19verified
On 19 March 2026 the FDA approved Wegovy HD, a higher 7.2 mg dose of semaglutide injection, for weight loss and long-term weight maintenance in certain adults, 54 days after filing under its national priority voucher pilot.
2026-03-18 · data · ●●○ · published 2026-03-18verified
The UN IGME child mortality report released on 18 March 2026 estimated that 4.9 million children died before age five in 2024, including 2.3 million newborns, and that the pace of reduction in child mortality has slowed by more than 60% since 2015.
2026-03-02 · policy · ●●○ · published 2026-03-02verified
PAHO announced on 2 March 2026 that its measles verification commission would review the measles elimination status of the United States and Mexico at its regular annual meeting in November 2026, instead of the 13 April 2026 meeting planned after outbreaks that began in January and February 2025.
2026-02-23 · policy · ●●○ · published 2026-02-23corrected
On 23 February 2026 the FDA issued its Plausible Mechanism draft guidance for approving individualized therapies for ultra-rare genetic diseases, such as genome editing and antisense oligonucleotides, when randomized controlled trials are not feasible, under which genome-editing products targeting different mutations in a single gene could be included in a single product application.
2026-02-13 · announcement · ●●○ · published 2026-02-18corrected
At its 54th meeting on 12–13 February 2026 (announced 18 February), the Global Fund Board welcomed the final Eighth Replenishment outcome of US$12.64 billion in total pledges and approved US$10.78 billion in country allocations for the 2026–2028 implementation period, while warning that funding gaps threaten progress toward ending HIV, tuberculosis and malaria.
- 2026-02-03 · The US FY2026 spending package signed on 3 February 2026 added $100 million for Alzheimer's and dementia research at the NIH, bringing total…
2026-02-03 · policy · ●●○ · published 2026-02-03corrected
The Consolidated Appropriations Act, 2026, signed on 3 February 2026, included the FY2026 Labor-HHS appropriations bill providing the National Institutes of Health $48.7 billion for biomedical research.
- 2026-02-03 · The US Consolidated Appropriations Act, 2026, signed on 3 February 2026, gave the National Cancer Institute $7.35 billion for FY2026, $128 m…
2026-02-02 · projection · ●●○ · published 2026-02-02verified
A Lancet Global Health study by ISGlobal (2 February 2026) projected that a severe drop in humanitarian and development aid could cause 22.6 million additional deaths by 2030 across 93 low- and middle-income countries, including 5.4 million children under five, and that even a milder 6%-per-year reduction could cause 9.4 million preventable deaths.
2026-01-22 · policy · ●●● · published 2026-01-22verified
On 22 January 2026 HHS and the State Department announced that the United States had completed its withdrawal from the World Health Organization, a year after giving notice, having stopped funding WHO and withdrawn all US personnel.
2026-01-21 · data · ●●○ · published 2026-01-21verified
The American Heart Association's 2026 Heart Disease and Stroke Statistics update (21 January 2026) reported 915,973 US cardiovascular deaths in 2023, with heart disease causing 22% and stroke 5.3% of US deaths, stroke replacing COVID-19 as the 4th leading cause of death, after a five-year pandemic-era rise in heart disease and stroke deaths reversed.
2026-01-11 · setback · ●●○ · published 2026-01-11corrected
On 11 January 2026 Vertex said it had completed enrollment in the Phase 1/2/3 study of zimislecel in people with type 1 diabetes and had temporarily postponed completion of dosing in the study, pending an ongoing internal manufacturing analysis.
2026-01-07 · announcement · ●●○ · published 2026-01-07corrected
On 7 January 2026 OpenAI introduced ChatGPT Health, a dedicated ChatGPT experience that connects users' health records and wellness apps, saying over 230 million people globally ask ChatGPT health and wellness questions every week.
- 2025 · Trinity College Dublin researchers identified in 2025 a genetic weak spot in DMG, a childhood brain cancer.
2025 · announcement · ●○○ · published 2026-01-04verified
Epigenetic reprogramming startup NewLimit raised a $130M Series B in 2025.
↳ corrects (or adds sources to) an earlier record: 2025: Epigenetic reprogramming startup NewLimit raised a $130M Series B in 2025.
- 2025 · Manchester researchers discovered in 2025 a melanoma immunotherapy resistance mechanism, with potential solutions.
2025 · announcement · ●○○ · published 2026-01-04corrected
Juvenescence raised $76 million in a Series D round.
↳ corrects (or adds sources to) an earlier record: 2025: Juvenescence, developing AI-enabled aging therapeutics, raised $76M (Series B-1) in 2025.
- 2025 · In 2025, researchers in Italy developed a new drug molecule for tumors sensitive to NEDD4 expression and activity.
- 2025 · Generation Lab raised an $11M seed round in 2025 for SystemAge, a 19-organ biological age test.
- 2025 · More than 18% of FDA's CDER and CBER employees were fired or quit in the first 9 months of 2025.
- 2025 · CNIO researchers reported in 2025 that a very high-fat diet could make cancer spread easier and blood-clotting molecules may play a role.
2025 · projection · ●●○ · published 2025-12-31legacy
A 2025 Nature Biotechnology projection estimated that widespread GLP-1 agonist use could reduce all-cause mortality by 6.4% by 2045.
- 2025 · The US FY2026 budget request proposed a 37.3% decrease in the National Cancer Institute budget from FY2025.
- 2025-11 · Phase IIb data reported in November 2025 showed concordant decreases in 11 organ-system epigenetic clocks with semaglutide treatment.
- 2025-11-24 · On 24 November 2025 oral semaglutide failed the Phase 3 evoke and evoke+ trials, showing no slowing of Alzheimer's disease progression.
- 2025-09 · UNITY Biotechnologies ceased operations following a clinical trial that was not impressive enough for the company to continue operating.
- 2025-03 · Federal funding for cancer research through March 2025 was 31% lower than in the same timeframe of the previous year.
- 2025-01-24 · On 24 January 2025 Retro Biosciences was reported to be raising a $1 billion Series A to extend human lifespan.